Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10945315,oral clearances,"In subjects in the extensive metabolizer group, coadministration of propafenone decreased oral clearances of R-(-)-mexiletine (from 41+/-11 L/h to 28+/-7 L/h) and S-(+)-mexiletine (from 43+/-15 L/h to 29+/-11 L/h) to an extent such that these values were no longer different between the extensive and the poor metabolizer groups.",Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945315/),[l] / [h],41,6655,DB01182,Propafenone
,10945315,oral clearances,"In subjects in the extensive metabolizer group, coadministration of propafenone decreased oral clearances of R-(-)-mexiletine (from 41+/-11 L/h to 28+/-7 L/h) and S-(+)-mexiletine (from 43+/-15 L/h to 29+/-11 L/h) to an extent such that these values were no longer different between the extensive and the poor metabolizer groups.",Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945315/),[l] / [h],28,6656,DB01182,Propafenone
,10945315,oral clearances,"In subjects in the extensive metabolizer group, coadministration of propafenone decreased oral clearances of R-(-)-mexiletine (from 41+/-11 L/h to 28+/-7 L/h) and S-(+)-mexiletine (from 43+/-15 L/h to 29+/-11 L/h) to an extent such that these values were no longer different between the extensive and the poor metabolizer groups.",Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945315/),[l] / [h],43,6657,DB01182,Propafenone
,10945315,oral clearances,"In subjects in the extensive metabolizer group, coadministration of propafenone decreased oral clearances of R-(-)-mexiletine (from 41+/-11 L/h to 28+/-7 L/h) and S-(+)-mexiletine (from 43+/-15 L/h to 29+/-11 L/h) to an extent such that these values were no longer different between the extensive and the poor metabolizer groups.",Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945315/),[l] / [h],29,6658,DB01182,Propafenone
<,15743979,Km,"In a substrate depletion assay without plasma, rat and human hepatocytes showed a concentration-dependent elimination of propafenone with low Km values (<0.4 microM).",Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15743979/),μM,0.4,21094,DB01182,Propafenone
,15743979,plasma binding (unbound fraction,"The differing effect of adding plasma in rat and human hepatocytes can be explained by species differences in plasma binding (unbound fraction, 0.0071 versus 0.0754 for rats and humans, respectively, at 0.1 microg/ml).",Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15743979/),,0.0071,21095,DB01182,Propafenone
,15743979,plasma binding (unbound fraction,"The differing effect of adding plasma in rat and human hepatocytes can be explained by species differences in plasma binding (unbound fraction, 0.0071 versus 0.0754 for rats and humans, respectively, at 0.1 microg/ml).",Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15743979/),,0.0754,21096,DB01182,Propafenone
,10591535,bioavailability,"However, bioavailability of propafenone dropped from 30 +/- 15% to 10 +/- 8% in extensive metabolizers (P < 0.01) and from 81 +/- 6% to 48 +/- 8% in poor metabolizers (P < 0.001).",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),%,30,22338,DB01182,Propafenone
,10591535,bioavailability,"However, bioavailability of propafenone dropped from 30 +/- 15% to 10 +/- 8% in extensive metabolizers (P < 0.01) and from 81 +/- 6% to 48 +/- 8% in poor metabolizers (P < 0.001).",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),%,10,22339,DB01182,Propafenone
,10591535,bioavailability,"However, bioavailability of propafenone dropped from 30 +/- 15% to 10 +/- 8% in extensive metabolizers (P < 0.01) and from 81 +/- 6% to 48 +/- 8% in poor metabolizers (P < 0.001).",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),%,81,22340,DB01182,Propafenone
,10591535,bioavailability,"However, bioavailability of propafenone dropped from 30 +/- 15% to 10 +/- 8% in extensive metabolizers (P < 0.01) and from 81 +/- 6% to 48 +/- 8% in poor metabolizers (P < 0.001).",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),%,48,22341,DB01182,Propafenone
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],4.1,22342,DB01182,Propafenone
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],23.5,22343,DB01182,Propafenone
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],3.4,22344,DB01182,Propafenone
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],16.0,22345,DB01182,Propafenone
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],123,22346,DB01182,Propafenone
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],457,22347,DB01182,Propafenone
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],43,22348,DB01182,Propafenone
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],112,22349,DB01182,Propafenone
,6872170,elimination half-life,"There was great intersubject variability in elimination half-life (mean 6 hr, range 2.4 to 11.8), steady-state mean concentration on 900 mg/day of propafenone (mean 1008 ng/ml, range 482 to 1812), and ""therapeutic"" plasma concentration (mean 588 ng/ml, range 64 to 1044).",Clinical pharmacology of propafenone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872170/),h,6,22753,DB01182,Propafenone
,6872170,steady-state mean concentration,"There was great intersubject variability in elimination half-life (mean 6 hr, range 2.4 to 11.8), steady-state mean concentration on 900 mg/day of propafenone (mean 1008 ng/ml, range 482 to 1812), and ""therapeutic"" plasma concentration (mean 588 ng/ml, range 64 to 1044).",Clinical pharmacology of propafenone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872170/),[ng] / [ml],1008,22754,DB01182,Propafenone
,6872170,plasma concentration,"There was great intersubject variability in elimination half-life (mean 6 hr, range 2.4 to 11.8), steady-state mean concentration on 900 mg/day of propafenone (mean 1008 ng/ml, range 482 to 1812), and ""therapeutic"" plasma concentration (mean 588 ng/ml, range 64 to 1044).",Clinical pharmacology of propafenone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872170/),[ng] / [ml],588,22755,DB01182,Propafenone
,4079594,t 1/2 alpha,"Mean values of main variables were t 1/2 alpha = 2.8 min, t 1/2 beta = 80 min, Kel = 0.12 min, -1, Vd beta = 1.6 1/kg, Cl = 1.03 1/h and AUR = 3.1 mg/h-1.",Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4079594/),min,2.8,23916,DB01182,Propafenone
,4079594,t 1/2 beta,"Mean values of main variables were t 1/2 alpha = 2.8 min, t 1/2 beta = 80 min, Kel = 0.12 min, -1, Vd beta = 1.6 1/kg, Cl = 1.03 1/h and AUR = 3.1 mg/h-1.",Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4079594/),min,80,23917,DB01182,Propafenone
,4079594,Kel,"Mean values of main variables were t 1/2 alpha = 2.8 min, t 1/2 beta = 80 min, Kel = 0.12 min, -1, Vd beta = 1.6 1/kg, Cl = 1.03 1/h and AUR = 3.1 mg/h-1.",Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4079594/),"-1·min,",0.12,23918,DB01182,Propafenone
,4079594,Vd beta,"Mean values of main variables were t 1/2 alpha = 2.8 min, t 1/2 beta = 80 min, Kel = 0.12 min, -1, Vd beta = 1.6 1/kg, Cl = 1.03 1/h and AUR = 3.1 mg/h-1.",Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4079594/),[1] / [kg],1.6,23919,DB01182,Propafenone
,4079594,Cl,"Mean values of main variables were t 1/2 alpha = 2.8 min, t 1/2 beta = 80 min, Kel = 0.12 min, -1, Vd beta = 1.6 1/kg, Cl = 1.03 1/h and AUR = 3.1 mg/h-1.",Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4079594/),[1] / [h],1.03,23920,DB01182,Propafenone
,4079594,AUR,"Mean values of main variables were t 1/2 alpha = 2.8 min, t 1/2 beta = 80 min, Kel = 0.12 min, -1, Vd beta = 1.6 1/kg, Cl = 1.03 1/h and AUR = 3.1 mg/h-1.",Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4079594/),[mg] / [h],3.1,23921,DB01182,Propafenone
,1442090,flow rate,"Separation of PPF, 5-OHP and NDP was achieved by reversed phase chromatography using a mobile phase consisting of 57% methanol and 43% 10 mmol/L potassium dibasic phosphate (pH 2.7) at a flow rate of 1.0 ml/min on a 5 microns ODS-C18 column.",[Simultaneous determination of propafenone and its active metabolite in serum by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442090/),[ml] / [min],1.0,26628,DB01182,Propafenone
,1442090,recoveries,"The recoveries of PPF, 5-OHP and NDP were found to be 99.54 +/- 2.13%, 100.02 +/- 3.66% and 100.48 +/- 3.10%, respectively.",[Simultaneous determination of propafenone and its active metabolite in serum by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442090/),%,99.54,26629,DB01182,Propafenone
,1442090,recoveries,"The recoveries of PPF, 5-OHP and NDP were found to be 99.54 +/- 2.13%, 100.02 +/- 3.66% and 100.48 +/- 3.10%, respectively.",[Simultaneous determination of propafenone and its active metabolite in serum by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442090/),%,100.02,26630,DB01182,Propafenone
,1442090,recoveries,"The recoveries of PPF, 5-OHP and NDP were found to be 99.54 +/- 2.13%, 100.02 +/- 3.66% and 100.48 +/- 3.10%, respectively.",[Simultaneous determination of propafenone and its active metabolite in serum by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442090/),%,100.48,26631,DB01182,Propafenone
,8220911,Kis,6. Sulphaphenazole competitively inhibits the 7- and in some samples partly (up to 50%) the 6-hydroxylation of S-warfarin as well as the 7-hydroxylation of R- and S-acenocoumarol and the 6-hydroxylation of S-acenocoumarol (Kis ranging from 0.5-1.3 microM).,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,0.5-1.3,27727,DB01182,Propafenone
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,99,27728,DB01182,Propafenone
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,117,27729,DB01182,Propafenone
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,219,27730,DB01182,Propafenone
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,7.2,27731,DB01182,Propafenone
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,6.1,27732,DB01182,Propafenone
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,7.7,27733,DB01182,Propafenone
,28985274,flow rate,"The chromatographic separation was achieved on a Hedera ODS-2C18 analytical column with the mobile phase of methanol and 5 mM ammonium acetate solution containing 0.2% formic acid (pH 3.2) (68:32, v/v) at a flow rate of 0.4 mL/min.",A Sensitive and Rapid LC-MS-MS Method for Simultaneous Determination of Propafenone and Its Active Metabolite 5-Hydroxypropafenone in Human Plasma and Its Application in a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985274/),[ml] / [min],0.4,28065,DB01182,Propafenone
,28985274,maximum peak plasma concentration (Cmax),"After oral administration of a single dose of 425 mg PPF hydrochloride sustained-release capsule, the maximum peak plasma concentration (Cmax) of PPF was 210.9 ± 141.9 ng/mL with a Tmax of 6 ± 1 h, the Cmax of 5-OHP was 129.6 ± 65.4 ng/mL with a Tmax of 7 ± 2 h.",A Sensitive and Rapid LC-MS-MS Method for Simultaneous Determination of Propafenone and Its Active Metabolite 5-Hydroxypropafenone in Human Plasma and Its Application in a Pharmacokinetic Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985274/),[ng] / [ml],210.9,28066,DB01182,Propafenone
,28985274,Tmax,"After oral administration of a single dose of 425 mg PPF hydrochloride sustained-release capsule, the maximum peak plasma concentration (Cmax) of PPF was 210.9 ± 141.9 ng/mL with a Tmax of 6 ± 1 h, the Cmax of 5-OHP was 129.6 ± 65.4 ng/mL with a Tmax of 7 ± 2 h.",A Sensitive and Rapid LC-MS-MS Method for Simultaneous Determination of Propafenone and Its Active Metabolite 5-Hydroxypropafenone in Human Plasma and Its Application in a Pharmacokinetic Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985274/),h,6,28067,DB01182,Propafenone
,28985274,Cmax,"After oral administration of a single dose of 425 mg PPF hydrochloride sustained-release capsule, the maximum peak plasma concentration (Cmax) of PPF was 210.9 ± 141.9 ng/mL with a Tmax of 6 ± 1 h, the Cmax of 5-OHP was 129.6 ± 65.4 ng/mL with a Tmax of 7 ± 2 h.",A Sensitive and Rapid LC-MS-MS Method for Simultaneous Determination of Propafenone and Its Active Metabolite 5-Hydroxypropafenone in Human Plasma and Its Application in a Pharmacokinetic Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985274/),[ng] / [ml],129.6,28068,DB01182,Propafenone
,28985274,Tmax,"After oral administration of a single dose of 425 mg PPF hydrochloride sustained-release capsule, the maximum peak plasma concentration (Cmax) of PPF was 210.9 ± 141.9 ng/mL with a Tmax of 6 ± 1 h, the Cmax of 5-OHP was 129.6 ± 65.4 ng/mL with a Tmax of 7 ± 2 h.",A Sensitive and Rapid LC-MS-MS Method for Simultaneous Determination of Propafenone and Its Active Metabolite 5-Hydroxypropafenone in Human Plasma and Its Application in a Pharmacokinetic Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985274/),h,7,28069,DB01182,Propafenone
,28985274,area under plasma concentration-time curve (AUC0-36),"The area under plasma concentration-time curve (AUC0-36) of PPF was 1610 ± 1309 ng·h/mL with a t1/2 of 4.6 ± 1.1 h, the AUC0-36 of 5-OHP was 1446 ± 754 ng·h/mL with a t1/2 of 7.6 ± 1.6 h.",A Sensitive and Rapid LC-MS-MS Method for Simultaneous Determination of Propafenone and Its Active Metabolite 5-Hydroxypropafenone in Human Plasma and Its Application in a Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985274/),[h·ng] / [ml],1610,28070,DB01182,Propafenone
,28985274,t1/2,"The area under plasma concentration-time curve (AUC0-36) of PPF was 1610 ± 1309 ng·h/mL with a t1/2 of 4.6 ± 1.1 h, the AUC0-36 of 5-OHP was 1446 ± 754 ng·h/mL with a t1/2 of 7.6 ± 1.6 h.",A Sensitive and Rapid LC-MS-MS Method for Simultaneous Determination of Propafenone and Its Active Metabolite 5-Hydroxypropafenone in Human Plasma and Its Application in a Pharmacokinetic Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985274/),h,4.6,28071,DB01182,Propafenone
,28985274,AUC0-36,"The area under plasma concentration-time curve (AUC0-36) of PPF was 1610 ± 1309 ng·h/mL with a t1/2 of 4.6 ± 1.1 h, the AUC0-36 of 5-OHP was 1446 ± 754 ng·h/mL with a t1/2 of 7.6 ± 1.6 h.",A Sensitive and Rapid LC-MS-MS Method for Simultaneous Determination of Propafenone and Its Active Metabolite 5-Hydroxypropafenone in Human Plasma and Its Application in a Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985274/),[h·ng] / [ml],1446,28072,DB01182,Propafenone
,28985274,t1/2,"The area under plasma concentration-time curve (AUC0-36) of PPF was 1610 ± 1309 ng·h/mL with a t1/2 of 4.6 ± 1.1 h, the AUC0-36 of 5-OHP was 1446 ± 754 ng·h/mL with a t1/2 of 7.6 ± 1.6 h.",A Sensitive and Rapid LC-MS-MS Method for Simultaneous Determination of Propafenone and Its Active Metabolite 5-Hydroxypropafenone in Human Plasma and Its Application in a Pharmacokinetic Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985274/),h,7.6,28073,DB01182,Propafenone
up to,6683556,bioavailabilities,The results show a dose dependence of bioavailability and maximum plasma concentrations after oral application with over-proportionate increase at higher dose levels yielding bioavailabilities up to 40-50% with single applications of 450 mg.,Investigations on the pharmacokinetics of propafenone in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683556/),%,40-50,31136,DB01182,Propafenone
,6683556,beta,The mean rate constant of elimination after intravenous application is beta = 0.28 h-1 (95% confidence limits: 0.24-0.33 h-1) corresponding to a half-life of 2.5 h.,Investigations on the pharmacokinetics of propafenone in man. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683556/),1/[h],0.28,31137,DB01182,Propafenone
,6683556,half-life,The mean rate constant of elimination after intravenous application is beta = 0.28 h-1 (95% confidence limits: 0.24-0.33 h-1) corresponding to a half-life of 2.5 h.,Investigations on the pharmacokinetics of propafenone in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683556/),h,2.5,31138,DB01182,Propafenone
,6683556,total plasma clearance,The total plasma clearance of 1.0 1/min (95% confidence limits: 0.9-1.1 1/min) is almost exclusively metabolic.,Investigations on the pharmacokinetics of propafenone in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683556/),[1] / [min],1.0,31139,DB01182,Propafenone
,2332982,distribution (Vdss,The pharmacokinetic parameters showed a large distribution (Vdss = 1021 +/- 211 L) and a high clearance (CI = 7019 +/- 1746 mL/min) of the drug.,Propafenone kinetics in the horse. Comparative analysis of compartmental and noncompartmental models. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2332982/),l,1021,36878,DB01182,Propafenone
,2332982,clearance (CI,The pharmacokinetic parameters showed a large distribution (Vdss = 1021 +/- 211 L) and a high clearance (CI = 7019 +/- 1746 mL/min) of the drug.,Propafenone kinetics in the horse. Comparative analysis of compartmental and noncompartmental models. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2332982/),[ml] / [min],7019,36879,DB01182,Propafenone
,3061720,systemic bioavailability,"It is well absorbed after oral administration, but systemic bioavailability is only 12% after a 300-mg dose.",Propafenone: a new antiarrhythmic agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),%,12,37633,DB01182,Propafenone
,3061720,elimination half-life,"Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers.",Propafenone: a new antiarrhythmic agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),h,5.5,37634,DB01182,Propafenone
,3061720,elimination half-life,"Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers.",Propafenone: a new antiarrhythmic agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),h,17.2,37635,DB01182,Propafenone
,15478341,flow rate,"Separation was developed on a reverse-phase tracer excel C18 column (25 x 0.46 cm i.d., 5 microm), using an acetonitrile-phosphate buffer gradient at a flow rate of 1.7 ml min(-1), and UV detection of 210 nm.",A rapid HPLC assay for the simultaneous determination of propafenone and its major metabolites in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15478341/),[ml] / [min],1.7,42504,DB01182,Propafenone
,10678105,Cl,"The Cl of Pro enantiomers in IM group was only about half of that in VEM group [(67 +/- 17) vs (133 +/- 28) L.h-1 for S-Pro, (90 +/- 24) vs (200 +/- 87) L.h-1 for R-Pro, P < 0.01].",CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10678105/),[l] / [h],67,54742,DB01182,Propafenone
,10678105,Cl,"The Cl of Pro enantiomers in IM group was only about half of that in VEM group [(67 +/- 17) vs (133 +/- 28) L.h-1 for S-Pro, (90 +/- 24) vs (200 +/- 87) L.h-1 for R-Pro, P < 0.01].",CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10678105/),[l] / [h],133,54743,DB01182,Propafenone
,10678105,Cl,"The Cl of Pro enantiomers in IM group was only about half of that in VEM group [(67 +/- 17) vs (133 +/- 28) L.h-1 for S-Pro, (90 +/- 24) vs (200 +/- 87) L.h-1 for R-Pro, P < 0.01].",CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10678105/),[l] / [h],90,54744,DB01182,Propafenone
,10678105,Cl,"The Cl of Pro enantiomers in IM group was only about half of that in VEM group [(67 +/- 17) vs (133 +/- 28) L.h-1 for S-Pro, (90 +/- 24) vs (200 +/- 87) L.h-1 for R-Pro, P < 0.01].",CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10678105/),[l] / [h],200,54745,DB01182,Propafenone
,1936057,t1/2 beta,"The pharmacokinetic parameters, derived from plasma levels, showed a t1/2 beta of 55.4 min, the central Vd/kg of 2.4 ml/kg, the Cl of 62.8 ml/min.",Tissue distribution of propafenone in the rat after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936057/),min,55.4,63409,DB01182,Propafenone
,1936057,central Vd/kg,"The pharmacokinetic parameters, derived from plasma levels, showed a t1/2 beta of 55.4 min, the central Vd/kg of 2.4 ml/kg, the Cl of 62.8 ml/min.",Tissue distribution of propafenone in the rat after intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936057/),[ml] / [kg],2.4,63410,DB01182,Propafenone
,1936057,Cl,"The pharmacokinetic parameters, derived from plasma levels, showed a t1/2 beta of 55.4 min, the central Vd/kg of 2.4 ml/kg, the Cl of 62.8 ml/min.",Tissue distribution of propafenone in the rat after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936057/),[ml] / [min],62.8,63411,DB01182,Propafenone
,1936057,AUC0-oo,kg and the AUC0-oo of 31.6 micrograms.min/ml.,Tissue distribution of propafenone in the rat after intravenous administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936057/),[min·μg] / [ml],31.6,63412,DB01182,Propafenone
,1936057,half-life,"The half-life values obtained for individual organs and tissues are similar to those obtained in plasma, around 1 h.",Tissue distribution of propafenone in the rat after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936057/),h,1,63413,DB01182,Propafenone
,2018005,lag time,"Well-absorbed, with a lag time of 4.4 to 9.8 minutes, 5-hydroxypropafenone reached peak concentrations of 153 to 337 ng/ml after 20 to 51 minutes.",Concentration-effect relations of 5-hydroxypropafenone in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2018005/),min,4.4 to 9.8,64389,DB01182,Propafenone
,2018005,peak concentrations,"Well-absorbed, with a lag time of 4.4 to 9.8 minutes, 5-hydroxypropafenone reached peak concentrations of 153 to 337 ng/ml after 20 to 51 minutes.",Concentration-effect relations of 5-hydroxypropafenone in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2018005/),[ng] / [ml],153 to 337,64390,DB01182,Propafenone
,2018005,terminal half-life,The terminal half-life was 506 to 963 minutes.,Concentration-effect relations of 5-hydroxypropafenone in normal subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2018005/),min,506 to 963,64391,DB01182,Propafenone
,10699379,S/R ratio,"After oral administration of 300 mg racemic PPF hydrochloride to 10 healthy Chinese subjects, the areas under the plasma concentration-time curves (AUCs) for (S)-PPF were significantly higher (S/R ratio, 1.50+/-0.17) and the apparent oral clearance significantly lower (S/R ratio, 0.68+/-0.07) than those parameters for (R)-PPF.",Stereoselective pharmacokinetics of propafenone and its major metabolites in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10699379/),,1,75273,DB01182,Propafenone
,10699379,S/R ratio,"After oral administration of 300 mg racemic PPF hydrochloride to 10 healthy Chinese subjects, the areas under the plasma concentration-time curves (AUCs) for (S)-PPF were significantly higher (S/R ratio, 1.50+/-0.17) and the apparent oral clearance significantly lower (S/R ratio, 0.68+/-0.07) than those parameters for (R)-PPF.",Stereoselective pharmacokinetics of propafenone and its major metabolites in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10699379/),,0.68,75274,DB01182,Propafenone
,8739818,trough concentrations,"Diprafenone caused a statistically significant increase in digoxin trough concentrations [1.4 (SD 0.2) vs 1.6 (0.3) ng.ml-1], AUC(zero)-24 values [41 (7) vs 48 (9) ng.h.ml-1 and Css-max[3.9 (0.6) vs 5.5 (0.9) ng.ml-1].",Effect of diprafenone on the pharmacokinetics of digoxin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[ng] / [ml],1.4,75800,DB01182,Propafenone
,8739818,trough concentrations,"Diprafenone caused a statistically significant increase in digoxin trough concentrations [1.4 (SD 0.2) vs 1.6 (0.3) ng.ml-1], AUC(zero)-24 values [41 (7) vs 48 (9) ng.h.ml-1 and Css-max[3.9 (0.6) vs 5.5 (0.9) ng.ml-1].",Effect of diprafenone on the pharmacokinetics of digoxin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[ng] / [ml],1.6,75801,DB01182,Propafenone
,8739818,AUC(zero)-24,"Diprafenone caused a statistically significant increase in digoxin trough concentrations [1.4 (SD 0.2) vs 1.6 (0.3) ng.ml-1], AUC(zero)-24 values [41 (7) vs 48 (9) ng.h.ml-1 and Css-max[3.9 (0.6) vs 5.5 (0.9) ng.ml-1].",Effect of diprafenone on the pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[h·ng] / [ml],41,75802,DB01182,Propafenone
,8739818,AUC(zero)-24,"Diprafenone caused a statistically significant increase in digoxin trough concentrations [1.4 (SD 0.2) vs 1.6 (0.3) ng.ml-1], AUC(zero)-24 values [41 (7) vs 48 (9) ng.h.ml-1 and Css-max[3.9 (0.6) vs 5.5 (0.9) ng.ml-1].",Effect of diprafenone on the pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[h·ng] / [ml],48,75803,DB01182,Propafenone
,8739818,Css-max,"Diprafenone caused a statistically significant increase in digoxin trough concentrations [1.4 (SD 0.2) vs 1.6 (0.3) ng.ml-1], AUC(zero)-24 values [41 (7) vs 48 (9) ng.h.ml-1 and Css-max[3.9 (0.6) vs 5.5 (0.9) ng.ml-1].",Effect of diprafenone on the pharmacokinetics of digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[ng] / [ml],3.9,75804,DB01182,Propafenone
,8739818,Css-max,"Diprafenone caused a statistically significant increase in digoxin trough concentrations [1.4 (SD 0.2) vs 1.6 (0.3) ng.ml-1], AUC(zero)-24 values [41 (7) vs 48 (9) ng.h.ml-1 and Css-max[3.9 (0.6) vs 5.5 (0.9) ng.ml-1].",Effect of diprafenone on the pharmacokinetics of digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[ng] / [ml],5.5,75805,DB01182,Propafenone
,8739818,trough concentration,"In all volunteers the parameters tended to return to the original values after administration of diprafenone was discontinued [1.4 (0.3) ng.ml-1, 39 (11) ng.h.ml-1, and 3.9 (1.1) ng.ml-1 for trough concentration, AUC(zero)-24 and Cmax respectively].",Effect of diprafenone on the pharmacokinetics of digoxin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[h·ng] / [ml],39,75806,DB01182,Propafenone
,8739818,trough concentration,"In all volunteers the parameters tended to return to the original values after administration of diprafenone was discontinued [1.4 (0.3) ng.ml-1, 39 (11) ng.h.ml-1, and 3.9 (1.1) ng.ml-1 for trough concentration, AUC(zero)-24 and Cmax respectively].",Effect of diprafenone on the pharmacokinetics of digoxin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[ng] / [ml],3.9,75807,DB01182,Propafenone
,8739818,AUC(zero)-24,"In all volunteers the parameters tended to return to the original values after administration of diprafenone was discontinued [1.4 (0.3) ng.ml-1, 39 (11) ng.h.ml-1, and 3.9 (1.1) ng.ml-1 for trough concentration, AUC(zero)-24 and Cmax respectively].",Effect of diprafenone on the pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[ng] / [ml],3.9,75808,DB01182,Propafenone
,8739818,Cmax,"In all volunteers the parameters tended to return to the original values after administration of diprafenone was discontinued [1.4 (0.3) ng.ml-1, 39 (11) ng.h.ml-1, and 3.9 (1.1) ng.ml-1 for trough concentration, AUC(zero)-24 and Cmax respectively].",Effect of diprafenone on the pharmacokinetics of digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[ng] / [ml],3.9,75809,DB01182,Propafenone
,2379537,total body clearance,"The total body clearance of propafenone was 963 ml/min, the terminal half-life 198 min and its absolute bioavailability was 15.5%.",Nonlinear kinetics of propafenone metabolites in healthy man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379537/),[ml] / [min],963,76719,DB01182,Propafenone
,2379537,terminal half-life,"The total body clearance of propafenone was 963 ml/min, the terminal half-life 198 min and its absolute bioavailability was 15.5%.",Nonlinear kinetics of propafenone metabolites in healthy man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379537/),min,198,76720,DB01182,Propafenone
,2379537,absolute bioavailability,"The total body clearance of propafenone was 963 ml/min, the terminal half-life 198 min and its absolute bioavailability was 15.5%.",Nonlinear kinetics of propafenone metabolites in healthy man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379537/),%,15.5,76721,DB01182,Propafenone
,8803526,AUCzero-last ratio,The only slow hydroxylator in this trial had an AUCzero-last ratio (with food/fasting) of 1.54.,Influence of food on the bioavailability and some pharmacokinetic parameters of diprafenone--a novel antiarrhythmic agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803526/),,1.54,86801,DB01182,Propafenone
,2619776,half-lives,"After acute intravenous (i.v.) administration of 3 mg/kg of 3H-labelled 2'[2-hydroxy-3-(1,1-dimethylpropylamino)propoxy]-3-phenylproiop henon hydrochloride ([3H]-diprafenone), plasma radioactivity levels declined biphasically with half-lives of 0.2 h (alpha-phase) and 1.5 h (beta-phase), respectively.",Pharmacokinetics and metabolism of the antiarrhythmic agent [3H]-diprafenone in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619776/),h,0.2,89524,DB01182,Propafenone
,2619776,half-lives,"After acute intravenous (i.v.) administration of 3 mg/kg of 3H-labelled 2'[2-hydroxy-3-(1,1-dimethylpropylamino)propoxy]-3-phenylproiop henon hydrochloride ([3H]-diprafenone), plasma radioactivity levels declined biphasically with half-lives of 0.2 h (alpha-phase) and 1.5 h (beta-phase), respectively.",Pharmacokinetics and metabolism of the antiarrhythmic agent [3H]-diprafenone in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619776/),h,1.5,89525,DB01182,Propafenone
,2619776,beta-half-life,"After acute oral administration of 9 mg/kg, absorption was prompt but continued, similar to a zero-order process, over many hours resulting in plateau-like plasma levels up to 5-6 h and a subsequent slow decline with a beta-half-life of 6-8 h.",Pharmacokinetics and metabolism of the antiarrhythmic agent [3H]-diprafenone in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619776/),h,6-8,89526,DB01182,Propafenone
,2619776,Absorption,Absorption varied between 50 and 80%.,Pharmacokinetics and metabolism of the antiarrhythmic agent [3H]-diprafenone in the rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619776/),%,50 and 80,89527,DB01182,Propafenone
,2619776,apparent volume of distribution (Varea),Radioactivity was distributed into subcellular organelles and the cytosol resulting in an apparent volume of distribution (Varea) of 4-5 l/kg.,Pharmacokinetics and metabolism of the antiarrhythmic agent [3H]-diprafenone in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619776/),[l] / [kg],4-5,89528,DB01182,Propafenone
,2619776,biliary excretion,"After oral application, biliary excretion varied between about 5 and 35% indicating protracted absorption.",Pharmacokinetics and metabolism of the antiarrhythmic agent [3H]-diprafenone in the rat. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619776/),%,5 and 35,89529,DB01182,Propafenone
,10824630,bioavailability,"However, bioavailability of propafenone dropped from 30% +/- 24% to 4% +/- 3% (P < .05).",Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824630/),%,30,90523,DB01182,Propafenone
,10824630,bioavailability,"However, bioavailability of propafenone dropped from 30% +/- 24% to 4% +/- 3% (P < .05).",Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824630/),%,4,90524,DB01182,Propafenone
,10824630,clearances,"After oral propafenone was administered, clearances through N-dealkylation (6 +/- 3 mL/min versus 26 +/- 16 mL/min; P < .05) and glucuronidation (178 +/- 75 mL/min versus 739 +/- 533 mL/min; P < .05), but not 5-hydroxylation, were increased by rifampin, indicating substantial enzyme induction.",Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824630/),[ml] / [min],6,90525,DB01182,Propafenone
,10824630,clearances,"After oral propafenone was administered, clearances through N-dealkylation (6 +/- 3 mL/min versus 26 +/- 16 mL/min; P < .05) and glucuronidation (178 +/- 75 mL/min versus 739 +/- 533 mL/min; P < .05), but not 5-hydroxylation, were increased by rifampin, indicating substantial enzyme induction.",Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824630/),[ml] / [min],26,90526,DB01182,Propafenone
,10824630,clearances,"After oral propafenone was administered, clearances through N-dealkylation (6 +/- 3 mL/min versus 26 +/- 16 mL/min; P < .05) and glucuronidation (178 +/- 75 mL/min versus 739 +/- 533 mL/min; P < .05), but not 5-hydroxylation, were increased by rifampin, indicating substantial enzyme induction.",Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824630/),[ml] / [min],178,90527,DB01182,Propafenone
,10824630,clearances,"After oral propafenone was administered, clearances through N-dealkylation (6 +/- 3 mL/min versus 26 +/- 16 mL/min; P < .05) and glucuronidation (178 +/- 75 mL/min versus 739 +/- 533 mL/min; P < .05), but not 5-hydroxylation, were increased by rifampin, indicating substantial enzyme induction.",Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824630/),[ml] / [min],739,90528,DB01182,Propafenone
,3221745,fu(R),This difference cannot be accounted for by the different degrees of protein binding of the enantiomers (fu(R) = 0.076; fu(S) = 0.049).,Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221745/),,0.,93110,DB01182,Propafenone
,3221745,fu(S),This difference cannot be accounted for by the different degrees of protein binding of the enantiomers (fu(R) = 0.076; fu(S) = 0.049).,Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221745/),,0.04,93111,DB01182,Propafenone
,9833596,CLO,"During dosing with racemic propafenone CLO of (S)- and (R)-propafenone averaged (+/-s.d.) 1226+751 and 1678+625 ml min(-1), respectively (P=0.024).",Stereoselective steady state disposition and action of propafenone in Chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833596/),[ml] / [min],1226,97008,DB01182,Propafenone
,9833596,CLO,"During dosing with racemic propafenone CLO of (S)- and (R)-propafenone averaged (+/-s.d.) 1226+751 and 1678+625 ml min(-1), respectively (P=0.024).",Stereoselective steady state disposition and action of propafenone in Chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833596/),[ml] / [min],1678,97009,DB01182,Propafenone
,9833596,CLO,Following the administration of the pure enantiomers CLO of (S)-propafenone increased (P= 0.007) to 2028+/-959 ml min(-1) and that of (R)-propafenone was reduced (P= 0.042) to 1318+/-867 ml min(-1).,Stereoselective steady state disposition and action of propafenone in Chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833596/),[ml] / [min],2028,97010,DB01182,Propafenone
,9833596,CLO,Following the administration of the pure enantiomers CLO of (S)-propafenone increased (P= 0.007) to 2028+/-959 ml min(-1) and that of (R)-propafenone was reduced (P= 0.042) to 1318+/-867 ml min(-1).,Stereoselective steady state disposition and action of propafenone in Chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833596/),[ml] / [min],1318,97011,DB01182,Propafenone
,19309751,flow rate,"After sample preparation, 2 microL were injected and separated with an isocratic mobile phase consisting of acetonitrile:0.1% formic acid (60:40, v/v) at a flow rate of 0.3 mL/min.",Development of a novel HPLC-MS/MS method for the determination of aconitine and its application to in vitro and rat microdialysis samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309751/),[ml] / [min],0.3,98167,DB01182,Propafenone
,19309751,relative recoveries,"The mean relative recoveries were 48.23% [coefficient of variation (CV 4.47%)] and 55.38% (CV 2.89%) for retrodialysis and recovery experiments, respectively.",Development of a novel HPLC-MS/MS method for the determination of aconitine and its application to in vitro and rat microdialysis samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309751/),%,48.23,98168,DB01182,Propafenone
,19309751,relative recoveries,"The mean relative recoveries were 48.23% [coefficient of variation (CV 4.47%)] and 55.38% (CV 2.89%) for retrodialysis and recovery experiments, respectively.",Development of a novel HPLC-MS/MS method for the determination of aconitine and its application to in vitro and rat microdialysis samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309751/),%,55.38,98169,DB01182,Propafenone
,19309751,in vivo recovery,The in vivo recovery of aconitine was 34.48% (CV 3.05%) and was stable over the 6 h study period.,Development of a novel HPLC-MS/MS method for the determination of aconitine and its application to in vitro and rat microdialysis samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309751/),%,34.48,98170,DB01182,Propafenone
,1981549,AUC ratio,"After all routes of administration, the AUC for the (-)-enantiomer was significantly higher than that of its antipode: the mean +/- SD values of (-):(+) AUC ratio were 1.99 +/- 0.228, 2.52 +/- 0.525, and 3.54 +/- 1.12 for the iv, ip, and po data, respectively.",Pharmacokinetics of propafenone enantiomers in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981549/),,1.99,102342,DB01182,Propafenone
,1981549,AUC ratio,"After all routes of administration, the AUC for the (-)-enantiomer was significantly higher than that of its antipode: the mean +/- SD values of (-):(+) AUC ratio were 1.99 +/- 0.228, 2.52 +/- 0.525, and 3.54 +/- 1.12 for the iv, ip, and po data, respectively.",Pharmacokinetics of propafenone enantiomers in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981549/),,2.52,102343,DB01182,Propafenone
,1981549,AUC ratio,"After all routes of administration, the AUC for the (-)-enantiomer was significantly higher than that of its antipode: the mean +/- SD values of (-):(+) AUC ratio were 1.99 +/- 0.228, 2.52 +/- 0.525, and 3.54 +/- 1.12 for the iv, ip, and po data, respectively.",Pharmacokinetics of propafenone enantiomers in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981549/),,3.54,102344,DB01182,Propafenone
,1981549,absolute bioavailabilities,"The respective absolute bioavailabilities of the (-)- and (+)-enantiomers were 0.422 and 0.254 after po administration and 0.493 and 0.402 after ip administration, indicating stereoselectivity in the first-pass metabolism of the drug.",Pharmacokinetics of propafenone enantiomers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981549/),,0.422,102345,DB01182,Propafenone
,1981549,absolute bioavailabilities,"The respective absolute bioavailabilities of the (-)- and (+)-enantiomers were 0.422 and 0.254 after po administration and 0.493 and 0.402 after ip administration, indicating stereoselectivity in the first-pass metabolism of the drug.",Pharmacokinetics of propafenone enantiomers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981549/),,0.254,102346,DB01182,Propafenone
,1981549,absolute bioavailabilities,"The respective absolute bioavailabilities of the (-)- and (+)-enantiomers were 0.422 and 0.254 after po administration and 0.493 and 0.402 after ip administration, indicating stereoselectivity in the first-pass metabolism of the drug.",Pharmacokinetics of propafenone enantiomers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981549/),,0.493,102347,DB01182,Propafenone
,1981549,absolute bioavailabilities,"The respective absolute bioavailabilities of the (-)- and (+)-enantiomers were 0.422 and 0.254 after po administration and 0.493 and 0.402 after ip administration, indicating stereoselectivity in the first-pass metabolism of the drug.",Pharmacokinetics of propafenone enantiomers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981549/),,0.402,102348,DB01182,Propafenone
,11749782,AUC,"The AUC (microg . h . L-1) of IM group was significantly higher than that of EM group (5126 +/- 1030 vs 2948 +/- 1230, P < 0.05).",Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749782/),[h·μg] / [l],5126,103491,DB01182,Propafenone
,11749782,AUC,"The AUC (microg . h . L-1) of IM group was significantly higher than that of EM group (5126 +/- 1030 vs 2948 +/- 1230, P < 0.05).",Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749782/),[h·μg] / [l],2948,103492,DB01182,Propafenone
,11749782,Ce50,"Whereas Ce50 (microg/L) was also greater in IM group than in EM group (747 +/- 281 vs 359 +/- 123, P < 0.05).",Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749782/),[μg] / [l],747,103493,DB01182,Propafenone
,11749782,Ce50,"Whereas Ce50 (microg/L) was also greater in IM group than in EM group (747 +/- 281 vs 359 +/- 123, P < 0.05).",Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749782/),[μg] / [l],359,103494,DB01182,Propafenone
,28929504,flow rate,"The mobile phase solution, comprising 1-pentanesulfonic acid sodium salt (0.1 m), acetonitrile and acetic acid (280:185:2.5, v/v/v), was pumped at a flow rate of 1 mL/min.",Simultaneous determination of serum propafenone and its metabolites using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28929504/),[ml] / [min],1,105435,DB01182,Propafenone
greater,28929504,recoveries,"The recoveries of propafenone, 5-OHP and NDPP were greater than 85, 82 and 60%, respectively, with the coefficients of variation (CVs) less than 5.4, 1.9 and 2.9%, respectively.",Simultaneous determination of serum propafenone and its metabolites using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28929504/),%,85,105436,DB01182,Propafenone
greater,28929504,recoveries,"The recoveries of propafenone, 5-OHP and NDPP were greater than 85, 82 and 60%, respectively, with the coefficients of variation (CVs) less than 5.4, 1.9 and 2.9%, respectively.",Simultaneous determination of serum propafenone and its metabolites using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28929504/),%,82,105437,DB01182,Propafenone
,28929504,recoveries,"The recoveries of propafenone, 5-OHP and NDPP were greater than 85, 82 and 60%, respectively, with the coefficients of variation (CVs) less than 5.4, 1.9 and 2.9%, respectively.",Simultaneous determination of serum propafenone and its metabolites using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28929504/),%,60,105438,DB01182,Propafenone
,28929504,recoveries,"The recoveries of propafenone, 5-OHP and NDPP were greater than 85, 82 and 60%, respectively, with the coefficients of variation (CVs) less than 5.4, 1.9 and 2.9%, respectively.",Simultaneous determination of serum propafenone and its metabolites using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28929504/),%,1,105439,DB01182,Propafenone
,28929504,recoveries,"The recoveries of propafenone, 5-OHP and NDPP were greater than 85, 82 and 60%, respectively, with the coefficients of variation (CVs) less than 5.4, 1.9 and 2.9%, respectively.",Simultaneous determination of serum propafenone and its metabolites using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28929504/),%,2,105440,DB01182,Propafenone
,17164694,oral clearance,Concomitant administration of propafenone decreased caffeine oral clearance from 8.3 +/- 0.9 L/h to 5.4 +/- 0.7 L/h (P < 0.05).,Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17164694/),[l] / [h],8.3,110982,DB01182,Propafenone
,17164694,oral clearance,Concomitant administration of propafenone decreased caffeine oral clearance from 8.3 +/- 0.9 L/h to 5.4 +/- 0.7 L/h (P < 0.05).,Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17164694/),[l] / [h],5.4,110983,DB01182,Propafenone
,10589372,bioavailability,"Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%.",Clinical pharmacokinetics of mexiletine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),%,90,113401,DB01182,Propafenone
,10589372,volume of distribution,Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals.,Clinical pharmacokinetics of mexiletine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),[l] / [kg],5 to 9,113402,DB01182,Propafenone
,10589372,elimination half-life,Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours).,Clinical pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),h,10,113403,DB01182,Propafenone
,11092591,flow-rate,"Separation of the diastereoisomeric propafenone glucuronides was achieved on a Spherisorb ODS 2 column (150 x 2.0 mm I.D., particle size 5 microm) at a flow-rate of 0.3 ml/min using a linear gradient from 20% B to 50% B in 15 min.",Determination of propafenone and its phase I and phase II metabolites in plasma and urine by high-performance liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11092591/),[ml] / [min],0.3,118698,DB01182,Propafenone
,6496371,Elimination half-life,"Elimination half-life is 5 to 8 hours in most patients, although a range of 2 to 32 hours has been reported.","Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6496371/),h,5 to 8,119028,DB01182,Propafenone
,6496371,Elimination half-life,"Elimination half-life is 5 to 8 hours in most patients, although a range of 2 to 32 hours has been reported.","Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6496371/),h,2 to 32,119029,DB01182,Propafenone
,2719900,steady-state plasma,"3. In patients with the extensive metabolizer phenotype, quinidine increased mean steady-state plasma propafenone concentrations more than two fold, from 408 +/- 351 (mean +/- s.d.) to 1096 +/- 644 ng ml-1 (P less than 0.001), decreased 5-hydroxypropafenone concentrations from 242 +/- 196 to 125 +/- 97 ng ml-1 (P less than 0.02) and reduced propafenone oral clearance by 58 +/- 23%.",Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719900/),[ng] / [ml],408,126193,DB01182,Propafenone
,2719900,steady-state plasma,"3. In patients with the extensive metabolizer phenotype, quinidine increased mean steady-state plasma propafenone concentrations more than two fold, from 408 +/- 351 (mean +/- s.d.) to 1096 +/- 644 ng ml-1 (P less than 0.001), decreased 5-hydroxypropafenone concentrations from 242 +/- 196 to 125 +/- 97 ng ml-1 (P less than 0.02) and reduced propafenone oral clearance by 58 +/- 23%.",Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719900/),[ng] / [ml],1096,126194,DB01182,Propafenone
,22749688,m/z,The mass transitions were m/z 428.3→279.3 for ranolazine and m/z 342.4→115.9 for propafenone.,Development and validation of a sensitive U-HPLC-MS/MS method with electrospray ionization for quantitation of ranolazine in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749688/),,428.3,131758,DB01182,Propafenone
,22749688,m/z,The mass transitions were m/z 428.3→279.3 for ranolazine and m/z 342.4→115.9 for propafenone.,Development and validation of a sensitive U-HPLC-MS/MS method with electrospray ionization for quantitation of ranolazine in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749688/),,279.3,131759,DB01182,Propafenone
,22749688,m/z,The mass transitions were m/z 428.3→279.3 for ranolazine and m/z 342.4→115.9 for propafenone.,Development and validation of a sensitive U-HPLC-MS/MS method with electrospray ionization for quantitation of ranolazine in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749688/),,342.4,131760,DB01182,Propafenone
,22749688,m/z,The mass transitions were m/z 428.3→279.3 for ranolazine and m/z 342.4→115.9 for propafenone.,Development and validation of a sensitive U-HPLC-MS/MS method with electrospray ionization for quantitation of ranolazine in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749688/),,115.9,131761,DB01182,Propafenone
<,22749688,run-time,"The validated method was a simple sample preparation procedure and short run-time (<2.0 min) method, which was successfully applied to a phase I pharmacokinetic study of ranolazine in Chinese healthy volunteers.",Development and validation of a sensitive U-HPLC-MS/MS method with electrospray ionization for quantitation of ranolazine in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749688/),min,2.0,131762,DB01182,Propafenone
,3817368,area under the plasmatic digoxin concentration curve (AUC 12h),During drug's association area under the plasmatic digoxin concentration curve (AUC 12h) increased on the average by 13.8% (from 19.27 +/- 6.002 ng hours/ml to 21.94 +/- 6.198 ng hours/ml: P less than 0.05) and by 19% at the first hour.,[Digoxin-propafenone interaction: values and limitations of plasma determination of the 2 drugs. Anti-arrhythmia effectiveness of propafenone]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3817368/),[h·ng] / [ml],19.27,150303,DB01182,Propafenone
,3817368,area under the plasmatic digoxin concentration curve (AUC 12h),During drug's association area under the plasmatic digoxin concentration curve (AUC 12h) increased on the average by 13.8% (from 19.27 +/- 6.002 ng hours/ml to 21.94 +/- 6.198 ng hours/ml: P less than 0.05) and by 19% at the first hour.,[Digoxin-propafenone interaction: values and limitations of plasma determination of the 2 drugs. Anti-arrhythmia effectiveness of propafenone]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3817368/),[h·ng] / [ml],21.94,150304,DB01182,Propafenone
,8422740,area under the plasma concentration time curve,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[h·μg] / [ml],81.7,152051,DB01182,Propafenone
,8422740,area under the plasma concentration time curve,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[h·μg] / [ml],76.3,152052,DB01182,Propafenone
,8422740,systemic,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[ml] / [kg·min],9.53,152053,DB01182,Propafenone
,8422740,systemic,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[ml] / [kg·min],10.27,152054,DB01182,Propafenone
,8422740,volume of distribution at steady state,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[l] / [kg],2.48,152055,DB01182,Propafenone
,8422740,volume of distribution at steady state,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[l] / [kg],2.64,152056,DB01182,Propafenone
,8422740,mean residence time,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),h,4.37,152057,DB01182,Propafenone
,8422740,mean residence time,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),h,4.47,152058,DB01182,Propafenone
,10336580,peak plasma concentrations,"For the EM subjects, S-PPF was less rapidly metabolized and had higher peak plasma concentrations than R-PPF (413+/-143 vs 291+/-109 ng ml-1, P<0.001).",The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336580/),[ng] / [ml],413,154915,DB01182,Propafenone
,10336580,peak plasma concentrations,"For the EM subjects, S-PPF was less rapidly metabolized and had higher peak plasma concentrations than R-PPF (413+/-143 vs 291+/-109 ng ml-1, P<0.001).",The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336580/),[ng] / [ml],291,154916,DB01182,Propafenone
,10336580,AUC,"The AUC was markedly higher for S-PPF than for R-PPF (2214+/-776 vs 1639+/-630 microg h l-1, P<0.001), whereas the clearance of S-PPF was significantly lower than that of R-PPF (96.0+/-39.0 vs 138+/-78 l h-1, P<0.01).",The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336580/),[h·μg] / [l],2214,154917,DB01182,Propafenone
,10336580,AUC,"The AUC was markedly higher for S-PPF than for R-PPF (2214+/-776 vs 1639+/-630 microg h l-1, P<0.001), whereas the clearance of S-PPF was significantly lower than that of R-PPF (96.0+/-39.0 vs 138+/-78 l h-1, P<0.01).",The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336580/),[h·μg] / [l],1639,154918,DB01182,Propafenone
,10336580,clearance,"The AUC was markedly higher for S-PPF than for R-PPF (2214+/-776 vs 1639+/-630 microg h l-1, P<0.001), whereas the clearance of S-PPF was significantly lower than that of R-PPF (96.0+/-39.0 vs 138+/-78 l h-1, P<0.01).",The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336580/),[l] / [h],96.0,154919,DB01182,Propafenone
,10336580,clearance,"The AUC was markedly higher for S-PPF than for R-PPF (2214+/-776 vs 1639+/-630 microg h l-1, P<0.001), whereas the clearance of S-PPF was significantly lower than that of R-PPF (96.0+/-39.0 vs 138+/-78 l h-1, P<0.01).",The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336580/),[l] / [h],138,154920,DB01182,Propafenone
,7568317,recovery rates,High recovery rates (80-95%) were achieved by means of a liquid-liquid-extraction at pH 11 with dichloromethane as solvent.,Quantitation of R- and S-propafenone and of the main metabolite in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7568317/),%,80-95,157196,DB01182,Propafenone
,7568317,k',The obtained capacity factors are k' = 2.36 for R-propafenone and k' = 3.82 for S-propafenone.,Quantitation of R- and S-propafenone and of the main metabolite in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7568317/),,2.36,157197,DB01182,Propafenone
,7568317,k',The obtained capacity factors are k' = 2.36 for R-propafenone and k' = 3.82 for S-propafenone.,Quantitation of R- and S-propafenone and of the main metabolite in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7568317/),,3.82,157198,DB01182,Propafenone
,14653957,metabolic ratios (,"The metabolic ratios (lg MR) of the three genotypes were -2.68+/-0.23, -2.2+/-0.7, and -1.1+/-0.5, respectively.",Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14653957/),,-,157357,DB01182,Propafenone
,14653957,metabolic ratios (,"The metabolic ratios (lg MR) of the three genotypes were -2.68+/-0.23, -2.2+/-0.7, and -1.1+/-0.5, respectively.",Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14653957/),,2.68,157358,DB01182,Propafenone
,14653957,metabolic ratios (,"The metabolic ratios (lg MR) of the three genotypes were -2.68+/-0.23, -2.2+/-0.7, and -1.1+/-0.5, respectively.",Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14653957/),,2.2,157359,DB01182,Propafenone
,14653957,metabolic ratios (,"The metabolic ratios (lg MR) of the three genotypes were -2.68+/-0.23, -2.2+/-0.7, and -1.1+/-0.5, respectively.",Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14653957/),,1.1,157360,DB01182,Propafenone
,14653957,AUC,"The AUC of the three groups were (1534+/-334), (1891+/-793), (3171+/-1075) microg.h.L(-1) for S-enantiomer and (1136+/-345), (1467+/-817), (2277+/-745) microg.h.L(-1) for R-enantiomer, respectively.",Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14653957/),[h·μg] / [l],1534,157361,DB01182,Propafenone
,14653957,AUC,"The AUC of the three groups were (1534+/-334), (1891+/-793), (3171+/-1075) microg.h.L(-1) for S-enantiomer and (1136+/-345), (1467+/-817), (2277+/-745) microg.h.L(-1) for R-enantiomer, respectively.",Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14653957/),[h·μg] / [l],1891,157362,DB01182,Propafenone
,14653957,AUC,"The AUC of the three groups were (1534+/-334), (1891+/-793), (3171+/-1075) microg.h.L(-1) for S-enantiomer and (1136+/-345), (1467+/-817), (2277+/-745) microg.h.L(-1) for R-enantiomer, respectively.",Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14653957/),[h·μg] / [l],3171,157363,DB01182,Propafenone
,14653957,AUC,"The AUC of the three groups were (1534+/-334), (1891+/-793), (3171+/-1075) microg.h.L(-1) for S-enantiomer and (1136+/-345), (1467+/-817), (2277+/-745) microg.h.L(-1) for R-enantiomer, respectively.",Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14653957/),[h·μg] / [l],1136,157364,DB01182,Propafenone
,14653957,AUC,"The AUC of the three groups were (1534+/-334), (1891+/-793), (3171+/-1075) microg.h.L(-1) for S-enantiomer and (1136+/-345), (1467+/-817), (2277+/-745) microg.h.L(-1) for R-enantiomer, respectively.",Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14653957/),[h·μg] / [l],1467,157365,DB01182,Propafenone
,14653957,AUC,"The AUC of the three groups were (1534+/-334), (1891+/-793), (3171+/-1075) microg.h.L(-1) for S-enantiomer and (1136+/-345), (1467+/-817), (2277+/-745) microg.h.L(-1) for R-enantiomer, respectively.",Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14653957/),[h·μg] / [l],2277,157366,DB01182,Propafenone
,3677541,alpha-phase half-life,"Mean postinfusion kinetic data were: alpha-phase half-life = 3.1 minutes, beta-phase half-life = 106.6 minutes, and gamma-phase half-life = 12.4 hours; volume of central compartment = 0.114 L/kg; steady-state volume of distribution = 0.67 L/kg; total clearance = 3.6 ml/min/kg; and renal clearance = 0.56 ml/min/kg.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),min,3.1,163609,DB01182,Propafenone
,3677541,beta-phase half-life,"Mean postinfusion kinetic data were: alpha-phase half-life = 3.1 minutes, beta-phase half-life = 106.6 minutes, and gamma-phase half-life = 12.4 hours; volume of central compartment = 0.114 L/kg; steady-state volume of distribution = 0.67 L/kg; total clearance = 3.6 ml/min/kg; and renal clearance = 0.56 ml/min/kg.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),min,106.6,163610,DB01182,Propafenone
,3677541,gamma-phase half-life,"Mean postinfusion kinetic data were: alpha-phase half-life = 3.1 minutes, beta-phase half-life = 106.6 minutes, and gamma-phase half-life = 12.4 hours; volume of central compartment = 0.114 L/kg; steady-state volume of distribution = 0.67 L/kg; total clearance = 3.6 ml/min/kg; and renal clearance = 0.56 ml/min/kg.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),h,12.4,163611,DB01182,Propafenone
,3677541,volume of central compartment,"Mean postinfusion kinetic data were: alpha-phase half-life = 3.1 minutes, beta-phase half-life = 106.6 minutes, and gamma-phase half-life = 12.4 hours; volume of central compartment = 0.114 L/kg; steady-state volume of distribution = 0.67 L/kg; total clearance = 3.6 ml/min/kg; and renal clearance = 0.56 ml/min/kg.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),[l] / [kg],0.114,163612,DB01182,Propafenone
,3677541,steady-state volume of distribution,"Mean postinfusion kinetic data were: alpha-phase half-life = 3.1 minutes, beta-phase half-life = 106.6 minutes, and gamma-phase half-life = 12.4 hours; volume of central compartment = 0.114 L/kg; steady-state volume of distribution = 0.67 L/kg; total clearance = 3.6 ml/min/kg; and renal clearance = 0.56 ml/min/kg.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),[l] / [kg],0.67,163613,DB01182,Propafenone
,3677541,total clearance,"Mean postinfusion kinetic data were: alpha-phase half-life = 3.1 minutes, beta-phase half-life = 106.6 minutes, and gamma-phase half-life = 12.4 hours; volume of central compartment = 0.114 L/kg; steady-state volume of distribution = 0.67 L/kg; total clearance = 3.6 ml/min/kg; and renal clearance = 0.56 ml/min/kg.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),[ml] / [kg·min],3.6,163614,DB01182,Propafenone
,3677541,renal clearance,"Mean postinfusion kinetic data were: alpha-phase half-life = 3.1 minutes, beta-phase half-life = 106.6 minutes, and gamma-phase half-life = 12.4 hours; volume of central compartment = 0.114 L/kg; steady-state volume of distribution = 0.67 L/kg; total clearance = 3.6 ml/min/kg; and renal clearance = 0.56 ml/min/kg.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),[ml] / [kg·min],0.56,163615,DB01182,Propafenone
,3677541,Absolute bioavailability,Absolute bioavailability was approximately 70% and peak plasma drug concentration occurred 2.3 hours after oral administration.,"Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),%,70,163616,DB01182,Propafenone
,3677541,Cumulative fraction excreted unchanged,"Cumulative fraction excreted unchanged in urine was approximately 15% and 9% of the dose after intravenous and oral administration, respectively.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),%,15,163617,DB01182,Propafenone
,3677541,Cumulative fraction excreted unchanged,"Cumulative fraction excreted unchanged in urine was approximately 15% and 9% of the dose after intravenous and oral administration, respectively.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),%,9,163618,DB01182,Propafenone
,16586461,area under the curve (AUC),The area under the curve (AUC) for the i.v. route was 5600.6 ng/ml.h and for oral administration the AUC was 3327.6 ng/ml.h.,Bioavailability of an extemporaneous suspension of propafenone made from tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586461/),[ng] / [h·ml],5600.6,164149,DB01182,Propafenone
,16586461,AUC,The area under the curve (AUC) for the i.v. route was 5600.6 ng/ml.h and for oral administration the AUC was 3327.6 ng/ml.h.,Bioavailability of an extemporaneous suspension of propafenone made from tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586461/),[ng] / [h·ml],3327.6,164150,DB01182,Propafenone
,16586461,bioavailability,The bioavailability was calculated at 59.41%.,Bioavailability of an extemporaneous suspension of propafenone made from tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16586461/),%,59.41,164151,DB01182,Propafenone
,6437721,apparent volume of distribution,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),l,"1300 to 11,000",168376,DB01182,Propafenone
,6437721,elimination half-life,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),d,53,168377,DB01182,Propafenone
,6437721,elimination half-life,"Although it has a short elimination half-life (1 to 3h), 2 major metabolites with antiarrhythmic effects accumulate in the plasma of patients during long term therapy.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,1 to 3,168378,DB01182,Propafenone
,6437721,elimination half-life,"Flecainide, another class Ic antiarrhythmic agent, has an elimination half-life of 14 hours which makes it suitable for twice daily dosing.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,14,168379,DB01182,Propafenone
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,9,168380,DB01182,Propafenone
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,28,168381,DB01182,Propafenone
,6437721,apparent volume of distribution,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),[l] / [kg],5.0 to 6.6,168382,DB01182,Propafenone
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,6 to 12,168383,DB01182,Propafenone
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,11 to 17,168384,DB01182,Propafenone
,10579479,metabolic ratios,"Mean CYP2D6 dextromethorphan metabolic ratios before and after fluoxetine therapy were 0.028 +/- 0.031 and 0.080 +/- 0.058, respectively (P = .001), indicating that a strong inhibition of CYP2D6 by fluoxetine activity was observed in Chinese subjects.",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),,0.028,169584,DB01182,Propafenone
,10579479,metabolic ratios,"Mean CYP2D6 dextromethorphan metabolic ratios before and after fluoxetine therapy were 0.028 +/- 0.031 and 0.080 +/- 0.058, respectively (P = .001), indicating that a strong inhibition of CYP2D6 by fluoxetine activity was observed in Chinese subjects.",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),,0.080,169585,DB01182,Propafenone
,10579479,oral clearance,"The elimination half-life, peak concentration, and area under the curve from 0 hours to infinity of two enantiomers after fluoxetine therapy were significantly increased compared with those at baseline (P < .01), whereas oral clearance decreased from 75.01 +/- 17.69 L/h to 49.36 +/- 8.62 L/h for S-propafenone (P = .005) and from 107.62 +/- 33.82 L/h to 70.60 +/- 12.42 L/h for R-propafenone (P = .027).",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),[l] / [h],75.01,169586,DB01182,Propafenone
,10579479,oral clearance,"The elimination half-life, peak concentration, and area under the curve from 0 hours to infinity of two enantiomers after fluoxetine therapy were significantly increased compared with those at baseline (P < .01), whereas oral clearance decreased from 75.01 +/- 17.69 L/h to 49.36 +/- 8.62 L/h for S-propafenone (P = .005) and from 107.62 +/- 33.82 L/h to 70.60 +/- 12.42 L/h for R-propafenone (P = .027).",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),[l] / [h],49.36,169587,DB01182,Propafenone
,10579479,oral clearance,"The elimination half-life, peak concentration, and area under the curve from 0 hours to infinity of two enantiomers after fluoxetine therapy were significantly increased compared with those at baseline (P < .01), whereas oral clearance decreased from 75.01 +/- 17.69 L/h to 49.36 +/- 8.62 L/h for S-propafenone (P = .005) and from 107.62 +/- 33.82 L/h to 70.60 +/- 12.42 L/h for R-propafenone (P = .027).",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),[l] / [h],107.62,169588,DB01182,Propafenone
,10579479,oral clearance,"The elimination half-life, peak concentration, and area under the curve from 0 hours to infinity of two enantiomers after fluoxetine therapy were significantly increased compared with those at baseline (P < .01), whereas oral clearance decreased from 75.01 +/- 17.69 L/h to 49.36 +/- 8.62 L/h for S-propafenone (P = .005) and from 107.62 +/- 33.82 L/h to 70.60 +/- 12.42 L/h for R-propafenone (P = .027).",Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579479/),[l] / [h],70.60,169589,DB01182,Propafenone
,10704025,absolute recoveries,"The extraction procedure resulted in absolute recoveries of 62.9 and 61.3% for (R)- and (S)-PPF, respectively, and of 57.6 and 56.5% for (R)- and (S)-PPF-5OH, respectively.",Simultaneous determination of propafenone and 5-hydroxypropafenone enantiomers in plasma by chromatography on an amylose derived chiral stationary phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704025/),%,62.9,170668,DB01182,Propafenone
,10704025,absolute recoveries,"The extraction procedure resulted in absolute recoveries of 62.9 and 61.3% for (R)- and (S)-PPF, respectively, and of 57.6 and 56.5% for (R)- and (S)-PPF-5OH, respectively.",Simultaneous determination of propafenone and 5-hydroxypropafenone enantiomers in plasma by chromatography on an amylose derived chiral stationary phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704025/),%,61.3,170669,DB01182,Propafenone
,10704025,absolute recoveries,"The extraction procedure resulted in absolute recoveries of 62.9 and 61.3% for (R)- and (S)-PPF, respectively, and of 57.6 and 56.5% for (R)- and (S)-PPF-5OH, respectively.",Simultaneous determination of propafenone and 5-hydroxypropafenone enantiomers in plasma by chromatography on an amylose derived chiral stationary phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704025/),%,57.6,170670,DB01182,Propafenone
,10704025,absolute recoveries,"The extraction procedure resulted in absolute recoveries of 62.9 and 61.3% for (R)- and (S)-PPF, respectively, and of 57.6 and 56.5% for (R)- and (S)-PPF-5OH, respectively.",Simultaneous determination of propafenone and 5-hydroxypropafenone enantiomers in plasma by chromatography on an amylose derived chiral stationary phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704025/),%,56.5,170671,DB01182,Propafenone
less,2756523,t1/2 el,Seven patients correspond to the extensive metabolizer phenotype with t1/2 el less than 10 h (mean: 5.4 +/- 2.2 SD).,[Pharmacokinetics of oral propafenone in patients with supraventricular arrhythmia]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2756523/),h,10,174157,DB01182,Propafenone
,2756523,t1/2 el,Seven patients correspond to the extensive metabolizer phenotype with t1/2 el less than 10 h (mean: 5.4 +/- 2.2 SD).,[Pharmacokinetics of oral propafenone in patients with supraventricular arrhythmia]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2756523/),h,5.4,174158,DB01182,Propafenone
,2756523,AUC final/AUC initial ratio,In this group t1/2 el increased from day 1 to day 4 and the AUC final/AUC initial ratio ranged between 4 to 17.5.,[Pharmacokinetics of oral propafenone in patients with supraventricular arrhythmia]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2756523/),,4 to 17.5,174159,DB01182,Propafenone
,2756523,t1/2 el,Three patients showed the non-extensive metabolizer phenotype with t1/2 el ranging from 12.4 to 13.7 h and a moderate increase in AUC over chronic dosing.,[Pharmacokinetics of oral propafenone in patients with supraventricular arrhythmia]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2756523/),h,12.4 to 13.7,174160,DB01182,Propafenone
,2285622,minimal effective concentrations,The minimal effective concentrations were lower after acute oral administration compared with chronic treatment both for propafenone (200 +/- 189 ng/ml vs. 492 +/- 530 ng/ml; p less than 0.05) and for 5-hydroxy-propafenone (82 +/- 40 ng/ml vs. 149 +/- 80 ng/ml; p less than 0.02).,Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285622/),[ng] / [ml],200,174259,DB01182,Propafenone
,2285622,minimal effective concentrations,The minimal effective concentrations were lower after acute oral administration compared with chronic treatment both for propafenone (200 +/- 189 ng/ml vs. 492 +/- 530 ng/ml; p less than 0.05) and for 5-hydroxy-propafenone (82 +/- 40 ng/ml vs. 149 +/- 80 ng/ml; p less than 0.02).,Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285622/),[ng] / [ml],492,174260,DB01182,Propafenone
,2285622,minimal effective concentrations,The minimal effective concentrations were lower after acute oral administration compared with chronic treatment both for propafenone (200 +/- 189 ng/ml vs. 492 +/- 530 ng/ml; p less than 0.05) and for 5-hydroxy-propafenone (82 +/- 40 ng/ml vs. 149 +/- 80 ng/ml; p less than 0.02).,Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285622/),[ng] / [ml],82,174261,DB01182,Propafenone
,2285622,minimal effective concentrations,The minimal effective concentrations were lower after acute oral administration compared with chronic treatment both for propafenone (200 +/- 189 ng/ml vs. 492 +/- 530 ng/ml; p less than 0.05) and for 5-hydroxy-propafenone (82 +/- 40 ng/ml vs. 149 +/- 80 ng/ml; p less than 0.02).,Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285622/),[ng] / [ml],149,174262,DB01182,Propafenone
,21508180,concentrations,"Throughout the study (follow-up, 199 ± 155 days), quinidine successfully inhibited CYP2D6: propafenone concentrations were 3 times higher in patients receiving quinidine (1033 ± 611 ng/mL vs 328 ± 229 ng/mL; P < .001).",Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508180/),ng,103,191444,DB01182,Propafenone
,21508180,concentrations,"Throughout the study (follow-up, 199 ± 155 days), quinidine successfully inhibited CYP2D6: propafenone concentrations were 3 times higher in patients receiving quinidine (1033 ± 611 ng/mL vs 328 ± 229 ng/mL; P < .001).",Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508180/),[ng] / [ml],328,191445,DB01182,Propafenone
,2911842,serum digoxin concentration,The mean +/- SD serum digoxin concentration (SDC) was 0.97 +/- 0.29 ng/ml before and 1.54 +/- 0.65 ng/ml (p less than 0.003) during propafenone administration.,Interaction between digoxin and propafenone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2911842/),[ng] / [ml],0.97,202517,DB01182,Propafenone
,2911842,serum digoxin concentration,The mean +/- SD serum digoxin concentration (SDC) was 0.97 +/- 0.29 ng/ml before and 1.54 +/- 0.65 ng/ml (p less than 0.003) during propafenone administration.,Interaction between digoxin and propafenone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2911842/),[ng] / [ml],1.54,202518,DB01182,Propafenone
,1409116,limit of detection,The limit of detection is 10 ng/ml for propafenone and 4 ng/ml for 5-hydroxypropafenone.,High-performance liquid chromatographic method for the simultaneous determination of propafenone and 5-hydroxypropafenone in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1409116/),[ng] / [ml],10,208443,DB01182,Propafenone
,1409116,limit of detection,The limit of detection is 10 ng/ml for propafenone and 4 ng/ml for 5-hydroxypropafenone.,High-performance liquid chromatographic method for the simultaneous determination of propafenone and 5-hydroxypropafenone in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1409116/),[ng] / [ml],4,208444,DB01182,Propafenone
,9653960,flow-rate,"The mobile phase used for the resolution of propafenone enantiomers and the internal standard propranolol was 0.25 M sodium perchlorate (pH 4.0)-acetonitrile (60:40, v/v), at a flow-rate of 0.7 ml/min.",Enantioselective analysis of propafenone in plasma using a polysaccharide-based chiral stationary phase under reversed-phase conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653960/),[ml] / [min],0.7,211507,DB01182,Propafenone
,9653960,recovery,"The method showed a mean recovery of 99.9% for (S)-propafenone and 100.5% for (R)-propafenone, and the coefficients of variation obtained in the precision and accuracy study were below 10%.",Enantioselective analysis of propafenone in plasma using a polysaccharide-based chiral stationary phase under reversed-phase conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653960/),%,99.9,211508,DB01182,Propafenone
,9653960,recovery,"The method showed a mean recovery of 99.9% for (S)-propafenone and 100.5% for (R)-propafenone, and the coefficients of variation obtained in the precision and accuracy study were below 10%.",Enantioselective analysis of propafenone in plasma using a polysaccharide-based chiral stationary phase under reversed-phase conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653960/),%,100.5,211509,DB01182,Propafenone
,28535452,flow rate,The chromatographic resolution was achieved on a BEH C18 column using a gradient mobile phase consisting of 0.1% formic acid in water and acetonitrile with 0.1% formic acid at flow rate of 0.6mL/min.,Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[ml] / [min],0.6,212955,DB01182,Propafenone
,28535452,Total run time of analysis,"Total run time of analysis was 1.1min and elution of PF, 5-OHPF, N-DPF and I.S. occurred at 0.69, 0.6, 0.68 and 0.73min, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),min,1.1,212956,DB01182,Propafenone
,28535452,AUC0-∞,"The key pharmacokinetic parameters AUC0-∞ and Cmax were 6057±1526, 2002±515 and 525±202 ng*h/mL and 653±183, 295±37.5 and 68.4±13.6ng/mL for PF, 5-OHPF and N-DPF, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[h·ng] / [ml],6057,212957,DB01182,Propafenone
,28535452,AUC0-∞,"The key pharmacokinetic parameters AUC0-∞ and Cmax were 6057±1526, 2002±515 and 525±202 ng*h/mL and 653±183, 295±37.5 and 68.4±13.6ng/mL for PF, 5-OHPF and N-DPF, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[h·ng] / [ml],2002,212958,DB01182,Propafenone
,28535452,AUC0-∞,"The key pharmacokinetic parameters AUC0-∞ and Cmax were 6057±1526, 2002±515 and 525±202 ng*h/mL and 653±183, 295±37.5 and 68.4±13.6ng/mL for PF, 5-OHPF and N-DPF, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[ng] / [ml],653,212959,DB01182,Propafenone
,28535452,Cmax,"The key pharmacokinetic parameters AUC0-∞ and Cmax were 6057±1526, 2002±515 and 525±202 ng*h/mL and 653±183, 295±37.5 and 68.4±13.6ng/mL for PF, 5-OHPF and N-DPF, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[h·ng] / [ml],2002,212960,DB01182,Propafenone
,28535452,Cmax,"The key pharmacokinetic parameters AUC0-∞ and Cmax were 6057±1526, 2002±515 and 525±202 ng*h/mL and 653±183, 295±37.5 and 68.4±13.6ng/mL for PF, 5-OHPF and N-DPF, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[h·ng] / [ml],525,212961,DB01182,Propafenone
,28535452,Cmax,"The key pharmacokinetic parameters AUC0-∞ and Cmax were 6057±1526, 2002±515 and 525±202 ng*h/mL and 653±183, 295±37.5 and 68.4±13.6ng/mL for PF, 5-OHPF and N-DPF, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[ng] / [ml],295,212962,DB01182,Propafenone
,28535452,Cmax,"The key pharmacokinetic parameters AUC0-∞ and Cmax were 6057±1526, 2002±515 and 525±202 ng*h/mL and 653±183, 295±37.5 and 68.4±13.6ng/mL for PF, 5-OHPF and N-DPF, respectively.",Highly sensitive UHPLC-MS/MS method for the simultaneous estimation of propafenone and its metabolites 5-hydroxypropafenone and N-depropylpropafenone on human dried blood spots technique and application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535452/),[ng] / [ml],68.4,212963,DB01182,Propafenone
,3712276,half-life of myocardial uptake (T1/2d),The mean half-life of myocardial uptake (T1/2d) was 22.3 +/- 5.9 min and the average time to approach steady-state tissue levels was 112 +/- 29 min.,Myocardial uptake kinetics and pharmacodynamics of propafenone in the isolated perfused rabbit heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712276/),min,22.3,213796,DB01182,Propafenone
,3712276,time to approach steady-state tissue levels,The mean half-life of myocardial uptake (T1/2d) was 22.3 +/- 5.9 min and the average time to approach steady-state tissue levels was 112 +/- 29 min.,Myocardial uptake kinetics and pharmacodynamics of propafenone in the isolated perfused rabbit heart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712276/),min,112,213797,DB01182,Propafenone
,3712276,T 1/2e,The T 1/2e averaged 26.0 +/- 9.4 min and did not differ significantly from T 1/2d.,Myocardial uptake kinetics and pharmacodynamics of propafenone in the isolated perfused rabbit heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712276/),min,26.0,213798,DB01182,Propafenone
,26579428,C max,"In Study B comparing SR-test with SR-reference the observed C max and AUC of propafenone for SR-test (124.5±140.0 ng/mL and 612.0±699.2 ng·h/mL, respectively) were higher than for SR-reference (78.52±72.92 ng/mL and 423.6±431.6 ng·h/mL, respectively) although the differences were not significant.",Pharmacokinetics of propafenone hydrochloride sustained-release capsules in male beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579428/),[ng] / [ml],124.5,218143,DB01182,Propafenone
,26579428,C max,"In Study B comparing SR-test with SR-reference the observed C max and AUC of propafenone for SR-test (124.5±140.0 ng/mL and 612.0±699.2 ng·h/mL, respectively) were higher than for SR-reference (78.52±72.92 ng/mL and 423.6±431.6 ng·h/mL, respectively) although the differences were not significant.",Pharmacokinetics of propafenone hydrochloride sustained-release capsules in male beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579428/),[ng] / [ml],78.52,218144,DB01182,Propafenone
,26579428,AUC,"In Study B comparing SR-test with SR-reference the observed C max and AUC of propafenone for SR-test (124.5±140.0 ng/mL and 612.0±699.2 ng·h/mL, respectively) were higher than for SR-reference (78.52±72.92 ng/mL and 423.6±431.6 ng·h/mL, respectively) although the differences were not significant.",Pharmacokinetics of propafenone hydrochloride sustained-release capsules in male beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579428/),[h·ng] / [ml],612.0,218145,DB01182,Propafenone
,26579428,AUC,"In Study B comparing SR-test with SR-reference the observed C max and AUC of propafenone for SR-test (124.5±140.0 ng/mL and 612.0±699.2 ng·h/mL, respectively) were higher than for SR-reference (78.52±72.92 ng/mL and 423.6±431.6 ng·h/mL, respectively) although the differences were not significant.",Pharmacokinetics of propafenone hydrochloride sustained-release capsules in male beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579428/),[h·ng] / [ml],423.6,218146,DB01182,Propafenone
,8289126,volume of distribution (Vdss,"Additionally, volume of distribution (Vdss = 6.5 B0.94) and clearance (CL = 0.17 B0.86) were correlated to body weight (B).",Species scaling of propafenone disposition and concentration--time relationships among eight mammalian species. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8289126/),,6.5,233452,DB01182,Propafenone
,8289126,clearance (CL,"Additionally, volume of distribution (Vdss = 6.5 B0.94) and clearance (CL = 0.17 B0.86) were correlated to body weight (B).",Species scaling of propafenone disposition and concentration--time relationships among eight mammalian species. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8289126/),,0.17,233453,DB01182,Propafenone
,2813154,total-body clearance,"After intravenous administration of 70 mg propafenone, total-body clearance was 10.5 ml/min/kg before and 10.4 ml/min/kg during hemodialysis.",Hemodialysis removal of propafenone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813154/),[ml] / [kg·min],10.5,238015,DB01182,Propafenone
,2813154,total-body clearance,"After intravenous administration of 70 mg propafenone, total-body clearance was 10.5 ml/min/kg before and 10.4 ml/min/kg during hemodialysis.",Hemodialysis removal of propafenone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813154/),[ml] / [kg·min],10.4,238016,DB01182,Propafenone
,2813154,clearance,"After a single oral dose of 300 mg, clearance was 19.4 ml/min/kg before and 18.9 ml/min/kg during hemodialysis.",Hemodialysis removal of propafenone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813154/),[ml] / [kg·min],19.4,238017,DB01182,Propafenone
,2813154,clearance,"After a single oral dose of 300 mg, clearance was 19.4 ml/min/kg before and 18.9 ml/min/kg during hemodialysis.",Hemodialysis removal of propafenone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813154/),[ml] / [kg·min],18.9,238018,DB01182,Propafenone
,2813154,Bioavailability,Bioavailability was 48%.,Hemodialysis removal of propafenone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813154/),%,48,238019,DB01182,Propafenone
,9792220,peak concentration,"1. After a single oral administration of 150 mg of propafenone, the average peak concentration of propafenone was 27.9+/-2.5 ng/ml, and that of 5-hydroxypropafenone was 61.7+/-6.6 ng/ml (n=5).",Kinetics of buccal absorption of propafenone single oral loading dose in healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9792220/),[ng] / [ml],27.9,243819,DB01182,Propafenone
,9792220,peak concentration,"1. After a single oral administration of 150 mg of propafenone, the average peak concentration of propafenone was 27.9+/-2.5 ng/ml, and that of 5-hydroxypropafenone was 61.7+/-6.6 ng/ml (n=5).",Kinetics of buccal absorption of propafenone single oral loading dose in healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9792220/),[ng] / [ml],61.7,243820,DB01182,Propafenone
,9792220,times to reach peak serum concentrations,"The times to reach peak serum concentrations of propafenone and 5-hydroxypropafenone were 1.8+/-0.1 hr and 1.5+/-0.2 hr, respectively.",Kinetics of buccal absorption of propafenone single oral loading dose in healthy humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9792220/),h,1.8,243821,DB01182,Propafenone
,9792220,times to reach peak serum concentrations,"The times to reach peak serum concentrations of propafenone and 5-hydroxypropafenone were 1.8+/-0.1 hr and 1.5+/-0.2 hr, respectively.",Kinetics of buccal absorption of propafenone single oral loading dose in healthy humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9792220/),h,1.5,243822,DB01182,Propafenone
,9792220,time to reach peak serum concentration,"2. After a buccal absorption of 150 mg of propafenone, the time to reach peak serum concentration of propafenone was 16.9+/-2.3 min (n=8).",Kinetics of buccal absorption of propafenone single oral loading dose in healthy humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9792220/),min,16.9,243823,DB01182,Propafenone
,9792220,peak concentration,"The average peak concentration of propafenone was 30.4+/-1.4 ng/ml (n=8), and the concentrations of 5-hydroxypropafenone were below the detection limit in all subjects.",Kinetics of buccal absorption of propafenone single oral loading dose in healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9792220/),[ng] / [ml],30.4,243824,DB01182,Propafenone
,28261841,retention times,"The retention times achieved were 1.36, 1.23, 1.24 min and 1.34 min for PPF, 5-OH PPF, NDP and IS (carbamazepine), respectively.","A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261841/),min,1.36,252731,DB01182,Propafenone
,28261841,retention times,"The retention times achieved were 1.36, 1.23, 1.24 min and 1.34 min for PPF, 5-OH PPF, NDP and IS (carbamazepine), respectively.","A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261841/),min,1.23,252732,DB01182,Propafenone
,28261841,retention times,"The retention times achieved were 1.36, 1.23, 1.24 min and 1.34 min for PPF, 5-OH PPF, NDP and IS (carbamazepine), respectively.","A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261841/),min,1.24,252733,DB01182,Propafenone
,28261841,retention times,"The retention times achieved were 1.36, 1.23, 1.24 min and 1.34 min for PPF, 5-OH PPF, NDP and IS (carbamazepine), respectively.","A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28261841/),min,1.34,252734,DB01182,Propafenone
,3063727,maximum concentration,The maximum concentration of propafenone in plasma was 993 +/- 532 ng/mL when propafenone was given alone compared with 1230 +/- 591 ng/mL when propafenone was given with cimetidine (P = .0622).,Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063727/),[ng] / [ml],993,256130,DB01182,Propafenone
,3063727,maximum concentration,The maximum concentration of propafenone in plasma was 993 +/- 532 ng/mL when propafenone was given alone compared with 1230 +/- 591 ng/mL when propafenone was given with cimetidine (P = .0622).,Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063727/),[ng] / [ml],1230,256131,DB01182,Propafenone
,3063727,PR interval,"When compared with cimetidine, propafenone significantly increased the PR interval from 161 +/- 5 msec to 192 +/- 6 msec (P less than .01) and the QRS duration from 89 +/- 3 msec to 98 +/- 4 msec (P less than .01).",Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063727/),ms,161,256132,DB01182,Propafenone
,3063727,PR interval,"When compared with cimetidine, propafenone significantly increased the PR interval from 161 +/- 5 msec to 192 +/- 6 msec (P less than .01) and the QRS duration from 89 +/- 3 msec to 98 +/- 4 msec (P less than .01).",Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063727/),ms,192,256133,DB01182,Propafenone
,26827781,Ki,Enzyme kinetics studies showed that DDPH was a competitive inhibitor of CYP2D1 and mixed inhibitor of CYP3A1 in rat liver microsomes with Ki values of 3.70 ± 0.42 μM and 4.79 ± 1.10 μM respectively.,"DDPH, a novel antihypertensive agent, is a potential dual inhibitor of hepatic CYP2D and CYP3A. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26827781/),μM,3.70,260368,DB01182,Propafenone
,26827781,Ki,Enzyme kinetics studies showed that DDPH was a competitive inhibitor of CYP2D1 and mixed inhibitor of CYP3A1 in rat liver microsomes with Ki values of 3.70 ± 0.42 μM and 4.79 ± 1.10 μM respectively.,"DDPH, a novel antihypertensive agent, is a potential dual inhibitor of hepatic CYP2D and CYP3A. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26827781/),μM,4.79,260369,DB01182,Propafenone
,26827781,Ki,"With human liver microsomes, DDPH was a noncompetitive inhibitor of CYP2D6 (Ki = 0.85 ± 0.06 μM) and mixed inhibitor of CYP3A (Ki = 2.15 ± 0.41 μM).","DDPH, a novel antihypertensive agent, is a potential dual inhibitor of hepatic CYP2D and CYP3A. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26827781/),μM,0.85,260370,DB01182,Propafenone
,26827781,Ki,"With human liver microsomes, DDPH was a noncompetitive inhibitor of CYP2D6 (Ki = 0.85 ± 0.06 μM) and mixed inhibitor of CYP3A (Ki = 2.15 ± 0.41 μM).","DDPH, a novel antihypertensive agent, is a potential dual inhibitor of hepatic CYP2D and CYP3A. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26827781/),μM,2.15,260371,DB01182,Propafenone
,3383990,plasma elimination half-life,"After 1 month of treatment the plasma elimination half-life of propafenone (6.7 h) was almost twice as long as after a single dose (3.5 h), and the area under the plasma propafenone concentration-time curve (7620 ng.ml-1.h) was significantly larger than after single dose (3522 ng.ml-1.h); this was also true for the metabolite.",Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383990/),h,6.7,260695,DB01182,Propafenone
,3383990,plasma elimination half-life,"After 1 month of treatment the plasma elimination half-life of propafenone (6.7 h) was almost twice as long as after a single dose (3.5 h), and the area under the plasma propafenone concentration-time curve (7620 ng.ml-1.h) was significantly larger than after single dose (3522 ng.ml-1.h); this was also true for the metabolite.",Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383990/),h,3.5,260696,DB01182,Propafenone
,3383990,area under the plasma propafenone concentration-time curve,"After 1 month of treatment the plasma elimination half-life of propafenone (6.7 h) was almost twice as long as after a single dose (3.5 h), and the area under the plasma propafenone concentration-time curve (7620 ng.ml-1.h) was significantly larger than after single dose (3522 ng.ml-1.h); this was also true for the metabolite.",Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383990/),[h·ng] / [ml],7620,260697,DB01182,Propafenone
,3383990,area under the plasma propafenone concentration-time curve,"After 1 month of treatment the plasma elimination half-life of propafenone (6.7 h) was almost twice as long as after a single dose (3.5 h), and the area under the plasma propafenone concentration-time curve (7620 ng.ml-1.h) was significantly larger than after single dose (3522 ng.ml-1.h); this was also true for the metabolite.",Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383990/),[h·ng] / [ml],3522,260698,DB01182,Propafenone
,7741777,S/R,"With regard to the two propafenone enantiomers, a preferential clearance of the R-form (S/R = 2.08 +/- 0.19) could be confirmed without observing a change in the S/R ratio with time.","Steady-state plasma kinetics of slow-release propafenone, its two isomers and its main metabolites. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741777/),,2.08,262320,DB01182,Propafenone
,3829342,elimination half-life,"EMs were characterized by a shorter propafenone elimination half-life (5.5 +/- 2.1 vs 17.2 +/- 8.0, p less than .001), lower average plasma concentration (Cp) (1.1 +/- 0.6 vs 2.5 +/- 0.5 ng/ml/mg daily dosage, p less than .001), and higher oral clearance (1115 +/- 1238 vs 264 +/- 48 ml/min, p less than .001).",Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829342/),,5.5,264409,DB01182,Propafenone
,3829342,elimination half-life,"EMs were characterized by a shorter propafenone elimination half-life (5.5 +/- 2.1 vs 17.2 +/- 8.0, p less than .001), lower average plasma concentration (Cp) (1.1 +/- 0.6 vs 2.5 +/- 0.5 ng/ml/mg daily dosage, p less than .001), and higher oral clearance (1115 +/- 1238 vs 264 +/- 48 ml/min, p less than .001).",Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829342/),,17.2,264410,DB01182,Propafenone
,3829342,plasma concentration (Cp),"EMs were characterized by a shorter propafenone elimination half-life (5.5 +/- 2.1 vs 17.2 +/- 8.0, p less than .001), lower average plasma concentration (Cp) (1.1 +/- 0.6 vs 2.5 +/- 0.5 ng/ml/mg daily dosage, p less than .001), and higher oral clearance (1115 +/- 1238 vs 264 +/- 48 ml/min, p less than .001).",Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829342/),[ng] / [daily·dosage·mg·ml],1.1,264411,DB01182,Propafenone
,3829342,plasma concentration (Cp),"EMs were characterized by a shorter propafenone elimination half-life (5.5 +/- 2.1 vs 17.2 +/- 8.0, p less than .001), lower average plasma concentration (Cp) (1.1 +/- 0.6 vs 2.5 +/- 0.5 ng/ml/mg daily dosage, p less than .001), and higher oral clearance (1115 +/- 1238 vs 264 +/- 48 ml/min, p less than .001).",Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829342/),[ng] / [daily·dosage·mg·ml],2.5,264412,DB01182,Propafenone
,3829342,oral clearance,"EMs were characterized by a shorter propafenone elimination half-life (5.5 +/- 2.1 vs 17.2 +/- 8.0, p less than .001), lower average plasma concentration (Cp) (1.1 +/- 0.6 vs 2.5 +/- 0.5 ng/ml/mg daily dosage, p less than .001), and higher oral clearance (1115 +/- 1238 vs 264 +/- 48 ml/min, p less than .001).",Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829342/),[ml] / [min],1115,264413,DB01182,Propafenone
,3829342,oral clearance,"EMs were characterized by a shorter propafenone elimination half-life (5.5 +/- 2.1 vs 17.2 +/- 8.0, p less than .001), lower average plasma concentration (Cp) (1.1 +/- 0.6 vs 2.5 +/- 0.5 ng/ml/mg daily dosage, p less than .001), and higher oral clearance (1115 +/- 1238 vs 264 +/- 48 ml/min, p less than .001).",Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829342/),[ml] / [min],264,264414,DB01182,Propafenone
,15856488,Retention times,"Retention times of FLU and an internal standard (propafenone) derivative were 15.5 and 13.5 min, respectively.","Determination of fluvoxamine in rat plasma by HPLC with pre-column derivatization and fluorescence detection using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15856488/),min,15.5,265649,DB01182,Propafenone
,15856488,Retention times,"Retention times of FLU and an internal standard (propafenone) derivative were 15.5 and 13.5 min, respectively.","Determination of fluvoxamine in rat plasma by HPLC with pre-column derivatization and fluorescence detection using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15856488/),min,13.5,265650,DB01182,Propafenone
,2612546,terminal half-life of elimination,"Following i.v. infusion of 50 mg diprafenone, the terminal half-life of elimination was 1.50 h, the volume of distribution at steady-state was 1.23 l.kg-1, and the free fraction in plasma was 1.68%.",Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612546/),h,1.50,268016,DB01182,Propafenone
,2612546,volume of distribution at steady-state,"Following i.v. infusion of 50 mg diprafenone, the terminal half-life of elimination was 1.50 h, the volume of distribution at steady-state was 1.23 l.kg-1, and the free fraction in plasma was 1.68%.",Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612546/),[l] / [kg],1.23,268017,DB01182,Propafenone
,2612546,free fraction,"Following i.v. infusion of 50 mg diprafenone, the terminal half-life of elimination was 1.50 h, the volume of distribution at steady-state was 1.23 l.kg-1, and the free fraction in plasma was 1.68%.",Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612546/),%,1.68,268018,DB01182,Propafenone
,2612546,total plasma clearance,"Mean total plasma clearance was 741 ml.min-1.70 kg-1, which approaches normal liver blood flow after correction for the blood/plasma concentration ratio.",Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612546/),[ml] / [70·kg·min],741,268019,DB01182,Propafenone
,2612546,bioavailability,"Following oral administration, a dose-dependent increase in bioavailability from 10.9 (50 mg dose) to 32.5% (150 mg dose) was observed.",Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612546/),%,10.9,268020,DB01182,Propafenone
,2612546,bioavailability,"Following oral administration, a dose-dependent increase in bioavailability from 10.9 (50 mg dose) to 32.5% (150 mg dose) was observed.",Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612546/),%,32.5,268021,DB01182,Propafenone
,19402341,Cmax,"Subjects (mean 25.9 +/- 5.3 years and 66.1 +/- 12.4 kg) had the following pharmacokinetic parameters: Cmax 189.9 +/- 20.92 ng/mL, Tmax 1.5 h, AUC 322.4 +/- 36.28 ng x ml(-1) x h for COM.",Comparative bioavailability of propafenone after administration of a magistral suspension vs. commercial tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402341/),[ng] / [ml],189.9,269153,DB01182,Propafenone
,19402341,Tmax,"Subjects (mean 25.9 +/- 5.3 years and 66.1 +/- 12.4 kg) had the following pharmacokinetic parameters: Cmax 189.9 +/- 20.92 ng/mL, Tmax 1.5 h, AUC 322.4 +/- 36.28 ng x ml(-1) x h for COM.",Comparative bioavailability of propafenone after administration of a magistral suspension vs. commercial tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402341/),h,1.5,269154,DB01182,Propafenone
,19402341,AUC,"Subjects (mean 25.9 +/- 5.3 years and 66.1 +/- 12.4 kg) had the following pharmacokinetic parameters: Cmax 189.9 +/- 20.92 ng/mL, Tmax 1.5 h, AUC 322.4 +/- 36.28 ng x ml(-1) x h for COM.",Comparative bioavailability of propafenone after administration of a magistral suspension vs. commercial tablets in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402341/),[h·ng] / [ml],322.4,269155,DB01182,Propafenone
,19402341,Cmax,"Values for MAG were Cmax 225.8 +/- 24.38 ng/mL, Tmax 1.7 h and AUC 359.3 +/- 27.90 ng x ml(-1) x h.",Comparative bioavailability of propafenone after administration of a magistral suspension vs. commercial tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402341/),[ng] / [ml],225.8,269156,DB01182,Propafenone
,19402341,Tmax,"Values for MAG were Cmax 225.8 +/- 24.38 ng/mL, Tmax 1.7 h and AUC 359.3 +/- 27.90 ng x ml(-1) x h.",Comparative bioavailability of propafenone after administration of a magistral suspension vs. commercial tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402341/),h,1.7,269157,DB01182,Propafenone
,19402341,AUC,"Values for MAG were Cmax 225.8 +/- 24.38 ng/mL, Tmax 1.7 h and AUC 359.3 +/- 27.90 ng x ml(-1) x h.",Comparative bioavailability of propafenone after administration of a magistral suspension vs. commercial tablets in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402341/),[h·ng] / [ml],359.3,269158,DB01182,Propafenone
,19402341,relative bioavailability,These values yielded a relative bioavailability of 111.42% for MAG compared with COM.,Comparative bioavailability of propafenone after administration of a magistral suspension vs. commercial tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402341/),%,111.42,269159,DB01182,Propafenone
,2708548,total body clearance,The total body clearance of digoxin during Phase I was 2.45 ml/min/kg and was 2.17 ml/min/kg during Phase II (NS) and decreased to 1.92 ml/min/kg during Phase III (P less than 0.05).,Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708548/),[ml] / [kg·min],2.45,270262,DB01182,Propafenone
,2708548,total body clearance,The total body clearance of digoxin during Phase I was 2.45 ml/min/kg and was 2.17 ml/min/kg during Phase II (NS) and decreased to 1.92 ml/min/kg during Phase III (P less than 0.05).,Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708548/),[ml] / [kg·min],2.17,270263,DB01182,Propafenone
,2708548,total body clearance,The total body clearance of digoxin during Phase I was 2.45 ml/min/kg and was 2.17 ml/min/kg during Phase II (NS) and decreased to 1.92 ml/min/kg during Phase III (P less than 0.05).,Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708548/),[ml] / [kg·min],1.92,270264,DB01182,Propafenone
,2708548,volume of distribution,"There was a trend towards a decrease in the volume of distribution of digoxin from 9.43 L/kg in Phase I, to 9.33 L/kg in Phase II, and 8.02 L/kg in Phase III.",Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708548/),[l] / [kg],9.43,270265,DB01182,Propafenone
,2708548,volume of distribution,"There was a trend towards a decrease in the volume of distribution of digoxin from 9.43 L/kg in Phase I, to 9.33 L/kg in Phase II, and 8.02 L/kg in Phase III.",Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708548/),[l] / [kg],9.33,270266,DB01182,Propafenone
,2708548,volume of distribution,"There was a trend towards a decrease in the volume of distribution of digoxin from 9.43 L/kg in Phase I, to 9.33 L/kg in Phase II, and 8.02 L/kg in Phase III.",Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708548/),[l] / [kg],8.02,270267,DB01182,Propafenone
,2708548,nonrenal clearance,Similarly there was a trend towards a decreased nonrenal clearance of digoxin from 1.21 ml/min/kg during Phase I to 1.01 ml/min/kg during Phase II and to 0.75 ml/min/kg during Phase III.,Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708548/),[ml] / [kg·min],1.21,270268,DB01182,Propafenone
,2708548,nonrenal clearance,Similarly there was a trend towards a decreased nonrenal clearance of digoxin from 1.21 ml/min/kg during Phase I to 1.01 ml/min/kg during Phase II and to 0.75 ml/min/kg during Phase III.,Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708548/),[ml] / [kg·min],1.01,270269,DB01182,Propafenone
,2708548,nonrenal clearance,Similarly there was a trend towards a decreased nonrenal clearance of digoxin from 1.21 ml/min/kg during Phase I to 1.01 ml/min/kg during Phase II and to 0.75 ml/min/kg during Phase III.,Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708548/),[ml] / [kg·min],0.75,270270,DB01182,Propafenone
,3732716,peak serum digoxin concentration,"Statistically significant changes were observed during propafenone in a number of digoxin kinetic indexes: a rise in peak serum digoxin concentration (4.30 vs 3.07 ng/ml - p less than 0.005), in area under the serum-digoxin concentration curve (4 h: 520.4 vs 368.9; 10 h: 789.6 vs 621.3 ng X min/ml - p less than 0.005; 24 h: 1187.6 vs 954.7 ng X min/ml - p less than 0.05) and urinary excretion of digoxin (277.7 vs 203.5 mcg - p less than 0.005).",[Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732716/),[ng] / [ml],4.30,272662,DB01182,Propafenone
,3732716,peak serum digoxin concentration,"Statistically significant changes were observed during propafenone in a number of digoxin kinetic indexes: a rise in peak serum digoxin concentration (4.30 vs 3.07 ng/ml - p less than 0.005), in area under the serum-digoxin concentration curve (4 h: 520.4 vs 368.9; 10 h: 789.6 vs 621.3 ng X min/ml - p less than 0.005; 24 h: 1187.6 vs 954.7 ng X min/ml - p less than 0.05) and urinary excretion of digoxin (277.7 vs 203.5 mcg - p less than 0.005).",[Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732716/),[ng] / [ml],3.07,272663,DB01182,Propafenone
,3732716,area under the serum-digoxin concentration curve,"Statistically significant changes were observed during propafenone in a number of digoxin kinetic indexes: a rise in peak serum digoxin concentration (4.30 vs 3.07 ng/ml - p less than 0.005), in area under the serum-digoxin concentration curve (4 h: 520.4 vs 368.9; 10 h: 789.6 vs 621.3 ng X min/ml - p less than 0.005; 24 h: 1187.6 vs 954.7 ng X min/ml - p less than 0.05) and urinary excretion of digoxin (277.7 vs 203.5 mcg - p less than 0.005).",[Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732716/),[min·ng] / [ml],520.4,272664,DB01182,Propafenone
,3732716,area under the serum-digoxin concentration curve,"Statistically significant changes were observed during propafenone in a number of digoxin kinetic indexes: a rise in peak serum digoxin concentration (4.30 vs 3.07 ng/ml - p less than 0.005), in area under the serum-digoxin concentration curve (4 h: 520.4 vs 368.9; 10 h: 789.6 vs 621.3 ng X min/ml - p less than 0.005; 24 h: 1187.6 vs 954.7 ng X min/ml - p less than 0.05) and urinary excretion of digoxin (277.7 vs 203.5 mcg - p less than 0.005).",[Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732716/),[min·ng] / [ml],368.9,272665,DB01182,Propafenone
,3732716,area under the serum-digoxin concentration curve,"Statistically significant changes were observed during propafenone in a number of digoxin kinetic indexes: a rise in peak serum digoxin concentration (4.30 vs 3.07 ng/ml - p less than 0.005), in area under the serum-digoxin concentration curve (4 h: 520.4 vs 368.9; 10 h: 789.6 vs 621.3 ng X min/ml - p less than 0.005; 24 h: 1187.6 vs 954.7 ng X min/ml - p less than 0.05) and urinary excretion of digoxin (277.7 vs 203.5 mcg - p less than 0.005).",[Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732716/),[min·ng] / [ml],789.6,272666,DB01182,Propafenone
,3732716,area under the serum-digoxin concentration curve,"Statistically significant changes were observed during propafenone in a number of digoxin kinetic indexes: a rise in peak serum digoxin concentration (4.30 vs 3.07 ng/ml - p less than 0.005), in area under the serum-digoxin concentration curve (4 h: 520.4 vs 368.9; 10 h: 789.6 vs 621.3 ng X min/ml - p less than 0.005; 24 h: 1187.6 vs 954.7 ng X min/ml - p less than 0.05) and urinary excretion of digoxin (277.7 vs 203.5 mcg - p less than 0.005).",[Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732716/),[min·ng] / [ml],621.3,272667,DB01182,Propafenone
,3732716,area under the serum-digoxin concentration curve,"Statistically significant changes were observed during propafenone in a number of digoxin kinetic indexes: a rise in peak serum digoxin concentration (4.30 vs 3.07 ng/ml - p less than 0.005), in area under the serum-digoxin concentration curve (4 h: 520.4 vs 368.9; 10 h: 789.6 vs 621.3 ng X min/ml - p less than 0.005; 24 h: 1187.6 vs 954.7 ng X min/ml - p less than 0.05) and urinary excretion of digoxin (277.7 vs 203.5 mcg - p less than 0.005).",[Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732716/),[min·ng] / [ml],1187.6,272668,DB01182,Propafenone
,3732716,24 h,"Statistically significant changes were observed during propafenone in a number of digoxin kinetic indexes: a rise in peak serum digoxin concentration (4.30 vs 3.07 ng/ml - p less than 0.005), in area under the serum-digoxin concentration curve (4 h: 520.4 vs 368.9; 10 h: 789.6 vs 621.3 ng X min/ml - p less than 0.005; 24 h: 1187.6 vs 954.7 ng X min/ml - p less than 0.05) and urinary excretion of digoxin (277.7 vs 203.5 mcg - p less than 0.005).",[Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732716/),[min·ng] / [ml],1187.6,272669,DB01182,Propafenone
,3732716,24 h,"Statistically significant changes were observed during propafenone in a number of digoxin kinetic indexes: a rise in peak serum digoxin concentration (4.30 vs 3.07 ng/ml - p less than 0.005), in area under the serum-digoxin concentration curve (4 h: 520.4 vs 368.9; 10 h: 789.6 vs 621.3 ng X min/ml - p less than 0.005; 24 h: 1187.6 vs 954.7 ng X min/ml - p less than 0.05) and urinary excretion of digoxin (277.7 vs 203.5 mcg - p less than 0.005).",[Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732716/),[min·ng] / [ml],954.7,272670,DB01182,Propafenone
,3732716,urinary excretion,"Statistically significant changes were observed during propafenone in a number of digoxin kinetic indexes: a rise in peak serum digoxin concentration (4.30 vs 3.07 ng/ml - p less than 0.005), in area under the serum-digoxin concentration curve (4 h: 520.4 vs 368.9; 10 h: 789.6 vs 621.3 ng X min/ml - p less than 0.005; 24 h: 1187.6 vs 954.7 ng X min/ml - p less than 0.05) and urinary excretion of digoxin (277.7 vs 203.5 mcg - p less than 0.005).",[Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732716/),mcg,277.7,272671,DB01182,Propafenone
,3732716,urinary excretion,"Statistically significant changes were observed during propafenone in a number of digoxin kinetic indexes: a rise in peak serum digoxin concentration (4.30 vs 3.07 ng/ml - p less than 0.005), in area under the serum-digoxin concentration curve (4 h: 520.4 vs 368.9; 10 h: 789.6 vs 621.3 ng X min/ml - p less than 0.005; 24 h: 1187.6 vs 954.7 ng X min/ml - p less than 0.05) and urinary excretion of digoxin (277.7 vs 203.5 mcg - p less than 0.005).",[Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732716/),mcg,203.5,272672,DB01182,Propafenone
